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Chronic Pulmonary Disease (CPD) often causes a reduction in physical activity and lower
limb dysfunction. Exercise tolerance generally declines across the stages of CPD, which might
be related to a reduction in physical activities of daily living, due to breathing discomfort or
increased leg/arm fatigue. The contributions of specific aspects of disease severity and
deconditioning to exercise tolerance remains unclear. In addition, it is uncertain whether patients
with CPD have reduced upper limb function, or if upper body aerobic training capacity (arm
ergometry) may be preserved. To provide insight into why patients adopt a more sedentary
lifestyle, the aims of this study were to determine: (1) the combined and individual contributions
of physical activities of daily living (type and volume) and FEV1 to arm and leg ergometry capacity
of patients with CPD; and (2) the predictability and odds ratio of high arm and leg ergometry
capacity in CPD individuals with high and low arm and leg strength, while controlling for stage of
disease, body composition and gender.
Forty-four CPD patients, 16 males and 28 females (mean age = 59.8 ± 11.9 years), with a
FEV1 of 22-89% predicted (mean FEV1% predicted = 54.6 ± 18.3) participated. All participants
completed spirometry, International Physical Activity Questionnaire and Activities of Daily
Living-Dyspnoea questionnaire, Medical Research Council grade, anthropometric assessment,
sub-maximal arm and leg ergometry testing, grip strength, and isokinetic quadriceps and
hamstrings strength and endurance testing. To determine contributing and predictor variables of
arm and leg ergometry capacity, a progressive statistical procedure was implemented leading to
multiple linear and binary regression analyses.
No statistically significant relationships (p>0.05) were found between total activity, upper body
activity and lower body activity, and peripheral muscle strength and aerobic capacity (controlling
for age, gender and percentage body fat). Multiple regression analysis demonstrated that
quadriceps strength (Nm), FEV1% and grip strength (kg) predicted 64% of peak wattage during
submaximal leg ergometry testing (adjusted R2 = 64%, F = 26.387, p=0.00). Quadriceps strength
showed the highest predictability of peak leg ergometry wattage (p=0.00, beta 0.844 and t=6.238),
followed by grip strength and FEV1% (p=0.038, β=-0.270, t=-2.143 and p=0.028, β=-0.230,
t=2.279, respectively).  A second regression analysis determined that quadriceps strength (Nm),
FEV1% and grip strength (kg) predicted 53% of peak wattage during submaximal arm ergometry
testing (adjusted R2=0.53, F=17.018, p=0.00). Quadriceps strength was the only independent
variable that showed predictability of peak arm ergometry wattage (p=0.00, beta 0.793 and
t=5.125). The odds ratio analysis indicated that CPD patients with high quadriceps strength have
13.76 times higher odds of having high peak arm ergometry wattage. This odds ratio equated to
an 85% probability of having high arm ergometry peak wattage if quadriceps strength is high.
In summary, the main factors predicting leg ergometry capacity were quadriceps strength
FEV1 and grip strength. Quadriceps strength was the only statistically significant predictor of peak
arm ergometry wattage, suggesting that a reduction in leg function is associated with a reduction
in arm function. This study highlights the importance of assessing upper and lower limb strength
in patients with CPD, and endorses the incorporation of specified lower limb strength training in
pulmonary rehabilitation, especially for those with reduced strength and physical activity levels.
Pulmonary rehabilitation programs should incorporate both aerobic exercise and lower limb
strength training.
1Chapter 1. Introduction
Chronic pulmonary disease (CPD) is a common medical term used to describe respiratory
conditions causing progressive airflow limitation that is not fully reversible (World Health
Organisation [WHO], 2013). Chronic pulmonary disease most commonly includes chronic
bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma,
interstitial lung disease, pulmonary hypertension and obstructive sleep apnoea syndrome. In New
Zealand, respiratory disease is a significant cause of morbidity and mortality, which places a major
burden on the healthcare system of New Zealand (National Health Committee [NHC], 2013). In
the mid-central region of the North Island of New Zealand, 95% of avoidable respiratory deaths
are caused by chronic obstructive pulmonary disease (COPD) and between 2-3% are due to
asthma (Central Region’s Technical Advisory Services Limited, 2008).
Effective management of CPD in New Zealand requires an integrated healthcare model. Specific
guidelines for the management of COPD are outlined by Abramson et al. (2009), on behalf of the
Thoracic Society of Australia and New Zealand and the Australian Lung Foundation in the
‘COPDX’ plan, which considers Confirming diagnosis (C), Optimising function (O), Preventing
deterioration (P), Developing support (D) and managing eXacerbations (X). Pulmonary
rehabilitation, with the main component being exercise training, is one goal of the ‘optimising
function’ category. Exercise-based rehabilitation is an important component in the management
of CPD, with the focus to improve physical function largely via an increase in exercise tolerance
(Eisner et al., 2011). The ability to exercise is a major limiting factor when it comes to the physical
rehabilitation of patients with CPD. Exercise capacity becomes limited as disease state
progresses, which is largely due to increasing symptoms and systemic complications. This can
prevent patients from exercising at an intensity or duration that provides sufficient overload which
is needed to elicit physiological adaptations (Koutedakis, Metsios, & Stavropoulos-Kalinoglou,
2006). Exercise intensity is often restricted to low levels in CPD in order to maintain an adequate
duration and vice versa, due to symptom limitations (Maltais et al., 1997). Accordingly, the
predominant focus of exercise-based rehabilitation for pulmonary patients is to gradually increase
cardiovascular function (aerobic capacity) by placing controlled but increasing demands on their
cardiovascular system (Cooper, 2003).
2The effectiveness of this exercise approach has been thoroughly researched and the consensus
is that the potential impact of exercise training is limited by the severity of the disease (Cooper,
2001; Sietsema, 2001). Killian et al. (1992) redirected the focus of research on exercise-based
rehabilitation away from pulmonary function and aerobic capacity, and focused on systemic
limitations. Compared to the degree of dyspnoea, a more crucial exercise training limitation during
maximal leg ergometry was the intensity of leg effort (Killian et al., 1992), confirming that disability
and treatment of CPD extends well beyond lung function.
The mechanisms responsible for leg fatigue during aerobic exercise in CPD patients were
discussed in a review study by Stendardi, Grazzini, Gigliotti, Lotti and Scano (2005). These
authors concluded that leg fatigue in patients with CPD during aerobic exercise occurs as a result
of blood flow redistribution and peripheral muscle alterations. When the body is hypoxic, as a
result of inadequate ventilation/perfusion, blood flow is redistributed away from the periphery to
the major organs (Kent et al., 2011). Blood flow to the working muscles during lower limb exercise
is further reduced when the respiratory muscles become fatigued, due to increased work of
breathing (Harms et al., 1997).
Over time, hypoxemia and the redistribution of blood flow results in structural changes to skeletal
muscle fibres (Sietsema, 2001; Kent et al., 2011). As forced expiratory volume in one second
(FEV1) decreases, inspiratory muscles become chronically overloaded due to the increased work
of breathing from hyperinflation and obstruction, causing an increase in type I muscle fibres in the
diaphragm (Levine et al., 2003). In the lower limbs, there is a reduction of type I (slow twitch
oxidative) fibres and augmentation of the proportion of type IIb (fast twitch glycolytic) fibres (Kim,
Mofarrahi, & Hussain, 2008). In further support, meta-analysis data reveal that the proportion of
type I fibres in the vastus lateralis correlates strongly with obstruction severity, as defined by FEV1
(r=0.56; p<0.001), and moderately with BMI1 (r=0.34; p<0.001) in patients with severe-very severe
COPD (Gosker, Zeegers, Wouters, & Schols, 2007b).
Moreover, a relationship has been established between leg fatigue, exercise tolerance and lower
limb muscle strength in cardiorespiratory patients (Hamilton, Killian, Summers, & Jones, 1995).
1 BMI = body mass index
3The authors made three important observations: 1) muscle strength contributed significantly to
the intensity of leg effort and dyspnoea at a given power output; 2) peak exercise capacity was
reduced in individuals with lower quadriceps strength; and 3) it was quantified that a doubling of
strength is associated with a decrease in leg effort by 25% and dyspnoea by 30%.  These findings
are important as they identified the impact of quadriceps strength on maximal work capacity and
severity of symptoms. This study concluded that cardiorespiratory patients have peripheral
muscle weakness (quadriceps strength) and that quadriceps strength was a significant contributor
to exercise capacity. The implication of this study was the emphasised need for assessment and
therapeutic management of lower limb dysfunction. Furthermore, a review by Debigaré and
Maltais (2008) concluded that exercise limitations of CPD patients is largely determined by lower
limb dysfunction, specifically fatigability, muscle atrophy, and structural muscle fibre changes,
which impacts lower body strength. Quadriceps strength in particular impacts dramatically on
quality of life and physical independence (Donaldson, Maddocks, Martolini, Polkey, & Man, 2012),
and strength has been reported as a significant predictor of healthcare utilisation in COPD
patients (Decramer, Gosselink, Troosters, Verschueren, & Evers, 1997).
Additionally, there is scientific evidence indicating that frequency of muscle recruitment and
activation in CPD patients largely determines the degree of dysfunction in a given muscle. In this
regard, researchers have demonstrated that the degree of skeletal muscle dysfunction in COPD
patients is not homogeneous between various muscle groups. For example, Franssen,
Broekhuizen, Janssen, Wouters, and Schols (2005) identified that COPD patients with skeletal
muscle dysfunction had a higher dysfunction in leg strength than in arm strength, when compared
to healthy individuals. Lower extremity muscles are chronically under-loaded due to inactivity and
disuse, while upper extremity muscles are less under-loaded (Kim et al., 2008). This under-
loading of the lower extremity muscles contributes to lower extremity muscle dysfunction. Poor
lower extremity functioning (as measured by the short performance physical battery) and poor
exercise performance is related to a greater risk of COPD-related disability (Eisner et al., 2011).
It was concluded that the management of COPD needs to be complimented with a comprehensive
rehabilitation programme including exercise training to help prevent poor lower extremity function
and COPD-related disability (Eisner et al., 2011).
4To date, lower limb function in CPD has received a lot of attention in the literature, however, fewer
studies have reported on upper limb function. There is still uncertainty regarding the comparative
declining effect of CPD on arm and leg function. Owens et al. (1988) compared arm and leg
ergometry in eight patients with moderate COPD and found that oxygen consumption during arm
and leg ergometry were the same at similar heart rate responses, even though arm ergometry
was at a significantly lower wattage. However, it is unclear from this study whether arm ergometry
results in less limb fatigue and/or dyspnoea at similar heart rates, and therefore an improved
ability to exercise. Franssen, Wouters, Baarends, Akkermans, and Schols (2002) investigated the
mechanical efficiency (determined by peak load of the exercise and the difference between
resting and exercise energy expenditure) of arm and leg exercise in patients with COPD
compared to healthy controls. In contrast to the findings of Owens et al. (1988), those patients
with COPD exhibited a preserved mechanical efficiency during sub-maximal arm exercise in
contrast with a markedly decreased leg efficiency, concluding that exercise tolerance of the upper
limbs appears to be relatively high in comparison to the lower limbs in COPD patients (Franssen
et al., 2002). However, they did not explore this concept at different stages of the disease. It is
unknown whether the progression of the disease affects the efficiency of arm exercise vs. leg
exercise.
Lower limb muscle function in CPD patients can be improved with physical exercise (Rochester,
2003). Improving leg strength and endurance may result in less leg fatigue (better exercise
tolerance) and improved functional exercise capacity during submaximal and maximal graded leg
ergometry testing. Arm ergometry may serve as an alternative method of exercise testing and
aerobic exercise training given the muscles of the upper limbs are less affected (less muscle fibre
redistribution and atrophy) compared to the lower limbs (Owens et al., 1988). As a consequence,
CPD patients may have the potential to perform upper limb exercise at higher heart rates for
longer without experiencing extremity muscle fatigue.
The ability to exercise generally declines across the stages of CPD progression. This reduction
might be related to individuals reducing their level of Physical Activities of Daily Living (PADL),
due to dyspnoea and/or increased leg/arm fatigue. The reasons why persons with CPD adopt a
more sedentary lifestyle are complex and could be dependent on the individual. Novel insights
5into the specific limitations of exercise are needed to develop effective exercise training
modalities, and ways to maintain physical activity levels in CPD patients.
There is a lack of scientific studies exploring whether CPD patients demonstrate better trainability
potential (ability to exercise for longer durations with less dyspnoea and limb fatigue) during arm
ergometry as compared to leg ergometry. Improvements in the trainability of CPD patients may
allow them to better maintain (if not improve) current aerobic capacity. In addition, it is unclear
from scientific studies whether a relationship exists between peripheral muscle strength and
PADL (type and volume), and whether there is an association between peripheral muscle strength
and the exercise trainability across stages of disease progression. Improvements in aerobic
capacity, along with muscular strength and endurance, will likely improve the physical functioning
of CPD patients in their everyday lives. This thesis therefore set out to explore these gaps in the
literature.
1.1. Aim of the thesis
This thesis aimed to:
1. investigate the combined and individual contributions of physical activities of daily living
(type and volume) and FEV1 to arm and leg ergometry capacity of patients with CPD;
2. determine the predictability and odds ratio of high arm and leg ergometry capacity in CPD
individuals with high and low arm and leg strength, while controlling for stage of disease,
body composition and gender.
It was hypothesised that:
1. Individuals that do more physical activities of daily living involving the arms and legs will
show better respective arm ergometry and leg ergometry capacity.
2. Independent of stage of disease, body composition and gender:
- leg strength contributes significantly to leg ergometry capacity; and
- arm strength contributes significantly to arm ergometry capacity.
6Chapter 2. Literature Review
Chapter 2 reviews the latest research findings relating to the upper and lower body aerobic
exercise capacity and strength of patients with CPD. The main focus of the literature discussed
in this section will be directed towards COPD, as the vast majority of the literature available on
the topic being discussed is specific to COPD. As there are marked similarities in pulmonary and
systemic manifestations of COPD and other chronic respiratory diseases (Goldstein, 2005;
Holland, Wadell, & Spruit, 2013), the information may be applied to other chronic respiratory
conditions. Additionally, in a clinical setting they undertake the same pulmonary exercise
rehabilitation programmes (Holland et al., 2013; Rochester, Fairburn, & Crouch, 2014).
2.1. Introduction to Chronic Pulmonary Disease
As previously stated in Chapter 1, the major determinant of CPD is chronic airflow limitation that
is not fully reversible, which is primarily due to increased airflow resistance as a result of
obstruction, inflammation, and/or damage to the airways and lung parenchyma (WHO, 2013).
Chronic pulmonary diseases have a progressive nature, and symptoms, namely breathlessness,
chronic cough, and increased phlegm production, can flare up during exacerbations (WHO,
2013). These diseases are often under diagnosed and can reach life threatening stages before
they are detected by medical professionals (Doherty, 2006).
2.1.1. Obstructive vs. Restrictive Pulmonary Diseases
Diagnosis of CPDs are based on symptoms, thorough examination of patient history, lung function
testing, and optimal treatment regimen trials (GOLD, 2014). Spirometry is used to assess lung
function by measuring the volume and flow of air inhaled and exhaled. The key values used for
diagnosis are forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and the
FEV1/FVC ratio. On conclusion of the spirometry test, the values are displayed as absolute
values, as well as percentage predicted value based on age, sex, height, weight and ethnicity.
Essentially, the values can then classify individuals into obstructive and restrictive pulmonary
disease categories as follows: obstruction is present when FEV1 is reduced compared to the
percentage and the FEV1/FVC ratio is < 0.7; and restriction is present if the FEV1/FVC ratio is >
0.7 and FVC is < 80% predicted (Mason et al., 2010). Additionally, some CPDs may present with
7a combination of obstruction and restriction when their FEV1/FVC ratio is > 0.7 but both their FEV1
and FVC% predicted values are reduced. It must be noted that some CPDs can cause obstruction
of the airways, but may not fit the diagnostic criteria of COPD. For example, the cause of the
obstruction may be a secondary complication of another CPD, such as asthma or bronchiectasis,
and not fit the diagnostic characteristics for COPD (Athanazio, 2012; Lange, 2013).
2.1.2. Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease is a predominant and thoroughly researched pulmonary
condition. It is an umbrella term that encompasses those lung conditions which become chronic,
cause obstruction of the airways, have a history of exposure to noxious gases, and result in
irreversible damage to the lungs. Chronic obstructive pulmonary disease is diagnosed, according
to GOLD (2014), as a post-bronchodilator FEV1/FVC ratio of <0.7, a history of exposure to noxious
gases, and a reduced FEV1. The World Health Organisation (WHO, 2008) stated that COPD
affects 210 million people worldwide, and has caused 3 million deaths annually. Furthermore, the
WHO (2008) predicted that by 2030 COPD will become the third leading cause of death
worldwide. Likewise, COPD has a considerable impact on the health of the New Zealand
population, affecting 15% of the adult population (200,000 people) older than 45 years of age
(WHO, 2008).
2.1.3. Other Chronic Pulmonary Diseases
Asthma is a chronic disease of the airways characterised by inflammation and bronchial
hypersensitivity resulting in intermittent episodes of semi-reversible/reversible airway obstruction
(Cruz, Bousquet, & Khaltaev, 2007). The key distinction between asthma and other chronic airway
diseases is that the airflow obstruction is reversible in the initial stages of the disorder, but as time
goes on, some patients will develop permanent obstruction as a consequence of airway
remodelling (NHC, 2013). It is estimated that there are currently 235 million people worldwide
who have been diagnosed with asthma (WHO, 2013), and 250,000 people worldwide die from
asthma annually. Asthma is generally known as a condition diagnosed in childhood, however
more and more adults and elderly individuals are being diagnosed. In 2006/07, 109,900 children
and 348,400 adults, or nearly 460,000 New Zealanders in total had been diagnosed with asthma
8(NHC, 2013).  In 2011/12, one in nine New Zealand adults (11.0%), and one in seven children
aged 16 years and younger (14.0%) had asthma (NHC, 2013).
Bronchiectasis is an abnormal, chronic enlargement of the bronchi. Patients with bronchiectasis
have a chronic cough, elevated phlegm production, and bacterial infections develop in the
enlarged bronchi that result in inflammation that furthers the bronchial damage and the loss of
lung function (O’Donnell, 2008). Diagnosis is made by high resolution computerise tomography.
Bronchiectasis is characterised by airflow obstruction, phlegm production and hyperinflation and
is associated with decreased health related quality of life and reduced functional exercise capacity
(O’Donnell, 2008). While bronchiectasis is often a complication of a previous lung infection or
injury, it could also be due to an underlying systemic illness (O’Donnell, 2008). According to NHC
(2013), clinical estimates of bronchiectasis in New Zealand are between 272 and 341 per 100,000
people, and the total cost of hospitalisation of patients with bronchiectasis have been
approximated to $5 million (1.9% of total costs).
Obstructive sleep apnoea (OSA) is characterised by recurring episodes of obstruction of the upper
airway during sleep preventing normal breathing, which may result in hypoxemia (Cruz et al.,
2007; Fauci et al., 2008). Causes of OSA include obesity, abnormal upper airway anatomy and/or
other obstructions of the upper airway passages (Fauci et al., 2008). According to a New Zealand-
based population survey, OSA affects approximately 4.4% and 4.1% of Māori and non-Māori
men, and 2.0% and 0.7%, Māori and non-Māori women, respectively (Mihaere et al., 2009). Total
annual healthcare burden of OSA for New Zealanders aged 30–60 years were estimated at a cost
of $40 million (NHC, 2013).
2.2. Severity of Chronic Pulmonary Disease
Due to the progressing nature of these diseases, early detection is important as, unfortunately,
death and disability eventuate (Doherty et al., 2006). In order for medical practitioners to diagnose
and determine severity COPD, Doherty et al. (2006) promotes the use of the medical research
council (MRC) dyspnoea scale, Global Initiative for Chronic Obstructive Lung Disease (GOLD)
classification and BODE index classification.
Based on FEV1% predicted values, GOLD (2014) has developed diagnostic and disease
classification guidelines (Table 2-1). These guidelines, along with the MRC scale, are commonly
9used in research to classify individuals into categories of disease severity. The MRC scale
classifies dyspnoea on a five point likert scale to determine severity of breathing impairment
during exercise, walking or typical activities of daily living.
Table 2-1.
The GOLD classification for diagnosis and classification of chronic obstructive pulmonary
disease.
Grade Stage Diagnostic Criteria*
I Mild FEV1 ≥ 80% predicted
II Moderate 50% ≥ FEV1 ≤ 80% predicted
III Severe 30% ≥ FEV1 ≤ 50 % predicted
IV Very Severe FEV1 < 30% predicted
Or FEV1 < 50% predicted plus chronic
respiratory failure
Note. *ratio FEV1/FVC < 0.7; chronic respiratory failure is defined as arterial partial pressure
of oxygen (PaO2) less than 8.0 kPa (60 mmHg) with or without arterial partial pressure of
CO2 (PaCO2) greater than 6.7 kPa (50 mmHg) while breathing air at sea level.
The BODE index includes walking ability measured by the six minute walk test as part of its
disease severity classification framework. The BODE index is a validated multidimensional
grading system and is regarded as a better predictor of death from respiratory causes than FEV1
alone (Doherty et al., 2006) and can predict the number of exacerbations in these individuals
(Marin et al., 2009). The BODE-index has four dimensions including: body mass index (B), degree
of airflow obstruction (O), dyspnoea (D), and exercise capacity (E).
Several organisations have developed guidelines for the classification and management of CPD,
including: GOLD classification (Vestbo et al., 2013), The American Thoracic Society/European
Respiratory Society (Celli et al., 2004), Canadian Thoracic Society (O’Donnell et al., 2008), and
The Thoracic Society of Australia and New Zealand (Abramson et al., 2009). The general
consensus is that disease severity range from mild to very severe, with a decreasing FEV1 and/or
FVC being classed as more severe.
Early detection is important as pulmonary rehabilitation is just as effective in the earlier stages of
CPD, and hence may delay disease progression (Chee & Sin, 2008; Takigawa et al., 2007).
Improving exercise capacity is important for the long term survival of COPD patients as exercise
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training can slow disease progression (Garcia-Aymerich, Lange, Benet, Schnohr, & Anto, 2007).
Measuring exercise capacity of patients with CPD is important, as they tend to have a reduced
exercise capacity compared to non-COPD individuals (Gosselink, Troosters, & Decramer, 1996;
Hamilton et al., 1995; Johnson-Warrington., 2014).
Few studies have reported on the physical activity patterns of people with CPD. In general, it
seems these patients prefer to avoid exercise and the reasons for that are not entirely clear.  From
this perspective there has been increasing awareness and scientific interest in the response of
individuals with CPD to exercise and the potential benefits of using planned/structured physical
activity and PADL to delay physical decline in people with CPD (American Thoracic
Society/European Respiratory Society, 2006).
2.3. Exercise Intolerance and Physical Inactivity in CPD patients.
Exercise tolerance and functional status are impaired in patients with CPD causing disability and
a decrease in quality of life (Eisner et al., 2011). Although the causes of the reduction on exercise
capacity in CPD are complex, some of this decline may be attributed to a reduction in physical
activity levels. Reduced levels of physical activity, such as less involvement in PADL, have been
reported in patients with CPD (Watz, Waschki, Meyer, & Magnussen, 2009b). Physical activity
becomes increasingly harder to perform as patients with CPD experience the progressive decline
in lung function (Celli, 1998).  The decline in lung function is accompanied by an increase in
symptoms, namely dyspnoea and/or leg fatigue, which leads to greater exercise limitation
(Cooper, 2001). The volume, intensity and duration of the physical activity is limited by the CPD
patient’s perception and severity of their symptoms.  As a result, a downward spiral can evolve,
as a greater reduction in the amount of PADL performed leads to further deconditioning (Préfaut,
Varray, & Vallet, 1995).
Exercise limitation in COPD patients results from a complex interaction of central (lungs) and
peripheral (limbs) factors (Debigaré & Maltais, 2008). Chronic Pulmonary Disease patients have
an increased metabolic demand due to abnormal gas exchange, hyperinflation, and increased
dead space ventilation, which leads to an increased work of breathing (Ofir, Laveneziana, Webb,
Lam, & O’Donnell, 2008). Respiratory muscles become overloaded to supply the body with
adequate oxygen, causing an increased demand of oxygen utilisation of the respiratory muscles,
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and resultant dyspnoea occurs (O’Donnell & Laveneziana, 2007). When oxygen demand is
increased during activity a smaller proportion of the already limited oxygen supply is available for
the working muscles (Laghi & Tobin, 2003). These respiratory complaints may contribute to the
systemic complications associated with CPD which contribute to leg fatigue.
2.3.1. Symptoms during exercise
Research indicates that exercise in COPD patients is often more limited by leg effort than
dyspnoea (Killian et al., 1992). Dyspnoea and leg effort were examined in COPD patients and
normal subjects during leg ergometry (Killian et al, 1992). Leg effort limited exercise in 46% of
COPD patients and 36% of normal subjects, whereas 26% of patients with COPD and 22% of
normal subjects were limited by dyspnoea.  However, this study did not compare dyspnoea and
leg effort ratings in varying degrees of airway obstruction. Leg effort might, as a consequence, be
more prevalent as a barrier to exercise as the disease progresses.
Hamilton et al. (1995) investigated the relationship of leg effort with peripheral muscle strength
and maximal exercise capacity in healthy individuals and patients with cardiorespiratory
disorders.  A significant relationship was found between maximal exercise capacity and
quadriceps strength in all groups. Likewise, a significant relationship was found between leg effort,
cycling wattage and quadriceps strength in all groups (p<0.001).  Poor quadriceps strength may
cause low power output and higher leg effort during exercise, suggesting that improving
quadriceps strength can decrease leg fatigue at a given exercise intensity. An important finding
was that for a given quadriceps strength, leg effort was greater for the cardiorespiratory patients
than normal subjects when cycling at the same intensity. This shows that cardiorespiratory
patients experience more leg effort than healthy subjects and therefore have greater exercise
limitations. Hamilton et al. (1995) concluded that in cardiorespiratory patients, leg fatigue is related
to leg strength and exercise capacity, which may be worsened with deconditioning. Moreover, in
CPD patients reduced PADL may lead to deconditioning (Préfaut et al., 1995), which may
contribute to the alterations in peripheral muscle function often seen in CPD patients (Gosselink
et al., 1996). Lower limb dysfunction in CPD patients is common and is caused by structural
changes to the muscle, which leads to a reduction in skeletal muscle strength and endurance
(Gosselink et al., 1996; Serres, Gautier, Préfaut, & Varray, 1998).
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2.4. Lower Limb Impairments in Chronic Pulmonary Diseases
Debigaré and Maltais (2008) illustrated that lower limb muscle dysfunction is caused by a
combination of anthropometrical and biochemical (physiological) impairments. These
impairments include a reduced cross-sectional area and muscle wasting and a muscle fibre shift
from type I to type IIb (Gosker et al., 2003), decreased muscle oxidative capacity and
capillarisation, and decreased mitochondrial function (Gosker, Hesselink, Duimel, Ward, &
Schols, 2007a). These non-respiratory, systemic impairments and functional limitations were
shown to be critical determinants of disability in patients with COPD (Eisner et al., 2011), and are
a major limitation to exercise in CPD (Debigaré & Maltais, 2008). Lower limb muscle dysfunction
is not always related to lung function, as such limitations have been evident across all stages of
CPD (Seymour et al., 2010; Donaldson et al., 2012). Seemingly, these physiological and
anthropometric impairments present as a reduction in lower limb strength and endurance.
2.4.1. Reduced lower limb strength
Reduced quadriceps strength and thigh cross sectional area have been reported in patients with
CPD, when compared to healthy individuals (Bernard et al., 1998). Impairment in lower limb
strength of people with CPD has an impact on the health care system, as a reduction in
quadriceps strength of CPD patients is associated with an increased utilization of health care
services (Decramer et al., 1997), and can be used as a predictor of mortality (Swallow et al.,
2007).
Peripheral muscle dysfunction, specifically quadriceps weakness, has been found across all
stages of COPD (Seymour et al., 2010), even in those with mild/moderate disease. However,
quadriceps weakness does not occur during moderate COPD with normal physical activity levels
and fat-free mass (FFM) (Degens, Sanchez, Horneros, Heijdra, Dekhuijzen, & Hopman, 2005).
Their findings suggest that lower limb dysfunction may be prevented by maintaining physical
activity levels and lower limb muscle mass (Degens et al., 2005). Early physical rehabilitation
interventions may be useful for avoiding the decline in physical activity associated with CPD and
aid in preserving lower limb muscle dysfunction and in preventing the associated exercise
limitations.
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Hamilton et al. (1995) quantified that a 2-fold increase in quadriceps strength was associated with
a 1.5-fold increase in maximal exercise capacity in cardiorespiratory patients. Their result
suggests that quadriceps strength can determine the intensity of exercise that CPD patients can
perform. Furthermore, they reported that a 2-fold increase in quadriceps strength was associated
with a 30% decrease in the intensity of leg fatigue at a given power output, suggesting that
strengthening the quadriceps can improve exercise tolerance and decrease symptoms
associated with CPD during exercise tolerance testing (Hamilton et al., 1995).
2.4.2. Reduced lower limb endurance
Lower limb exercise endurance is significantly impaired in CPD patients when compared with
healthy controls (Serres et al., 1998). Moreover, quadriceps endurance has been reported to be
more affected in CPD patients than quadriceps strength (Coronell et al., 2004). Specifically,
Coronell et al. (2004) reported that quadriceps endurance was reduced by 77% and quadriceps
strength was reduced by 43% in CPD patients, compared to healthy controls. The impairment in
quadriceps endurance was present even in those with mild to moderate COPD with normal
physical activity levels. Their findings demonstrated the importance of muscle endurance testing
and may explain the reduction in cycling endurance time seen in COPD (Coronell et al., 2004).
Contractile fatigue of the quadriceps occurs after cycling in a significant proportion of patients with
COPD (Saey et al., 2003), which may limit cycling duration. After bronchodilation, no significant
improvements in cycling endurance time (measured by cycling at a constant rate of 80% of the
peak wattage obtained during a maximal incremental leg ergometer test) were shown in those
who experience quadriceps fatigue, suggesting that peripheral muscle fatigue is involved in
limiting exercise endurance in patients with COPD (Saey et al., 2003). Furthermore, a smaller
increase in cycling endurance time of patients with COPD was seen after bronchodilation in those
who report leg fatigue as the main limiting symptom, compared to dyspnoea (Deschênes, Pepin,
Saey, LeBlanc, & Maltais, 2008).
Leg fatigue tolerance at the end of exercise and aerobic capacity were independently related to
cycling endurance time (Vivodtzev et al., 2011). The authors speculated that non-respiratory
impairments may be stronger determinants of endurance time than air flow limitation, as the
differences in endurance time occurred independently of pulmonary function.
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2.4.3. Relationship of lower limb dysfunction and severity of air flow obstruction
Changes in peripheral muscle dysfunction accelerate with ascending disease severity causing a
decrease in physical function (Eliason, Abdel-Halim, Arvidsson, Kadi, & Piehl-Aulin, 2009). This
finding indicates that those with increasing CPD severity have greater functional limitations. The
relationship between aspects of lower limb muscle dysfunction and disease severity will now be
discussed.
Associations between disease severity (FEV1) and quadriceps structure and function have been
reported. For example, quadriceps strength and muscle cross sectional area have displayed
positive correlations with FEV1% predicted (Bernard et al., 1998). Additionally, meta-analysis data
revealed that the proportion of type I fibres in the vastus lateralis correlated with FEV1 and BMI in
patients with moderate to severe COPD (Gosker et al., 2007b).
While the above findings of Bernard et al. (1998) show that a reduction in quadriceps strength
may increase with disease progression, quadriceps weakness is present across all stages of
disease severity. For instance, Seymour et al. (2010) found significant differences in quadriceps
strength between healthy individuals and CPD patients for all GOLD stages. Despite the fact that
the highest percentage of patients with quadriceps weakness was in GOLD stage 4 (38%),
quadriceps weakness was apparent at early stages (GOLD stage 1).
Moreover, maximum cycling wattage has been strongly associated with FEV1 (r=0.71, p>0.05)
(Haccoun, Smountas, Gibbons, Bourbeau, & Lands, 2002). In this study, a combination of FEV1
and quadriceps endurance explained most of the variability in maximum cycling wattage
(Haccoun et al., 2002). Similarly, Serres et al. (1998) demonstrated that disease severity, physical
activity levels and lower limb endurance are inter-related and the authors speculated that the
three variables are cofactors that progress together. Their findings demonstrated that FEV1
correlated moderately with quadriceps endurance (r=0.52, p<0.05) and physical activity levels
(r=0.63, p<0.05) (Serres et al., 1998). Physical inactivity is apparent across all stages of COPD,
with a gradual decrease across the stages (Troosters et al., 2010). Exercise intolerance is
apparent in CPD patients as of GOLD stage I, which begins to have an impact of PADL as of
GOLD stage 2 (Díaz et al., 2013).
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Likewise, Jehn et al. (2011) demonstrated that daily walking activity is indicative of disease
severity in 107 patients with COPD (GOLD stage 2-4). Steps per day, time spent walking (at
passive, active and fast paced intensities), and total walking time differed significantly between
GOLD stages 2-4, and fast walking was negatively associated with GOLD stage, BODE index,
and the MRC dyspnoea scale. Walking time (min/day) and intensity were significant and
independent predictors of a BODE score ≥ 6. These findings indicate that walking time and
intensity are significant and independent predictors of disease severity and can be used to predict
the probability of poor prognosis of patients with COPD using the BODE index. Jehn et al. (2011)
concluded that exercise training is needed in COPD patients to improve functional capacity and
walking ability to potentially slow the progression of the disease. To date, the main body of
literature has investigated exercise tolerance specific to the lower limbs. There has been little
focus on the role of the upper limbs in the reduction of physical activity levels, exercise intolerance
and increase in disease severity.
2.4.4. Upper limb vs. lower limb function
Ventilation and heart rate are higher for arm ergometry during both maximal and submaximal
exercise at a given level of oxygen consumption (Owens et al., 1988). During maximal ergometry
testing, the maximum ventilation and heart rates achieved were similar for arm ergometry and leg
ergometry, however the maximum wattage and oxygen consumption obtained were lower for the
arms. It is unclear from this study whether arm ergometry resulted in more or less dyspnoea
and/or limb fatigue at similar heart rates or oxygen consumption. Castagna, Boussuges, Vallier,
Prefaut, and Brisswalter (2007) reported no significant differences in dyspnoea severity between
peak arm and leg exercise COPD patients. The authors observed differences between arm and
leg aerobic capacity in COPD patients and only a slight reduction in arm exercise capacity was
reported in COPD patients compared to healthy controls. Additionally, no statistically significant
differences were seen in mechanical efficiency during arm exercise between COPD and controls,
but mechanical efficiency was significantly decreased during leg cycling in COPD. These findings
suggest that there is less upper limb dysfunction in COPD compared to lower limb.
Upper limb muscle strength (triceps and biceps) and handgrip strength have been shown to be
significantly reduced in CPD patients compared to healthy controls (Clark, Cochrane, Mackay, &
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Paton, 2000; Gosselink et al., 1996). In contrast, Heijdra et al. (2003) showed no differences in
handgrip strength between patients with CPD and controls, however this was based on an
average of 3 attempts rather than the maximum. Peripheral muscle weakness has been apparent
in the upper body along with the lower body, however, upper limb strength appears to be better
preserved compared to lower limb strength in patients with CPD (Bernard et al., 1998). Their
findings demonstrated that lower body strength (quadriceps), upper body strength (pectoralis
major and latissimus dorsi), and thigh cross sectional area were all significantly reduced in COPD
when compared to healthy controls, however, the reduction in strength and type I fibres were
proportionately greater for the quadriceps than the pectoralis major and latissimus dorsi (Bernard
et al., 1998). In contrast, Franssen et al. (2005) reported that quadriceps and biceps strength
were significantly reduced compared to healthy controls, and they were equally affected (65 ±
3% and 67 ± 3% respectively). When the participants were split into fat free mass depleted and
non-FFM depleted COPD patients, quadriceps strength and endurance were significantly lower
in the FFM depleted subgroup, however, biceps strength and endurance and handgrip strength
were comparable between the two subgroups. This finding suggests that more of the muscle
atrophy in the FFM depleted participants occurred in the lower limbs compared to the upper limbs.
These above findings suggest that upper limb function is somewhat preserved as lower limb
endurance declines in COPD patients. Chronic Pulmonary Disease patients may reduce the use
of their lower limbs (potentially through a decrease in walking), while the use of the upper limbs
remain unchanged, however no studies were found which compared upper and lower limb activity
levels. During rest, the shoulder girdle muscles are often used as accessory respiratory muscles
to help facilitate the increase in breathing resistance, and are as a consequence quite active
during quiet breathing in COPD patients (Bevegard, Freyschuss, & Strandell, 1966).  Recruitment
of accessory respiratory muscles could mean that the upper extremity muscles are less under
loaded than the lower extremity, and could be the reason for the apparent preservation of upper
limb function. However in patients with COPD, arm activity results in a significant increase in
metabolic and ventilatory demand, which is emphasised during arm elevation, resulting in
dyspnoea, dynamic hyperinflation, and a consequent decrease in performance during arm
specific PADL (Celli, Rassulo, & Make, 1986; Martinez, Couser, & Celli, 1991; Velloso et al.,
2003). During arm specific PADL the muscles of the shoulder girdle are used as accessory
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muscles of respiration due to the increased work in breathing, causing an increase in oxygen
demand (Laghi & Tobin, 2003). Ventilatory constraints and the resultant breathlessness causes
limitation during arm specific PADL, which highlight the importance of upper limb exercise training
(Velloso, Stella, Cendon, Silva, & Jardim, 2003). Upper limb exercise training may reduce the
physical demands of PADL involving the upper limbs, as Couser, Martinez, and Celli (1993)
reported that eight weeks of upper limb exercise training (including arm ergometry and
unsupported arm exercise) resulted in significantly reduced ventilatory and metabolic demands
during unsupported arm exercise testing.
2.5. Body Composition
Low BMI and FFM are common in CPD patients, and can be used to predict poor prognosis
(Schols, Broekhuizen, Weling-Scheepers, & Wouters, 2005). A BMI of <21 as part of the BODE
index decreases the likelihood of long term survival in CPD (Doherty et al, 2006). While a BMI of
<18.5 kg.m2 is considered underweight according to the WHO, a BMI of <21 km.m2 is considered
the underweight cut off in CPD (Celli et al, 2004; ATS, 2014). Low BMI in CPD (<21 kg.m2) is
more common in severe stages due to muscle atrophy (Eliason et al, 2009). Body mass index is
a simple method of classifying individuals into body mass categories, however it does not
measure the components of body composition. Assessing FFM in CPD needs consideration, as
reduced FFM levels have been reported in male and female CPD patients with a normal BMI
(Vestbo et al, 2006). Fat-free mass is an independent predictor of mortality in CPD (Schols et al.,
2005), which supports the use of body composition assessment when considering severity of
disease in CPD patients.
On the other hand, a higher BMI has been associated with higher FEV1% predicted (Vibhuti et al,
2007), and a BMI >25 emerged as an independent predictor of better long term survival in CPD
patients (Lainscak et al, 2011). A BMI greater than 25 is likely to improve patient prognosis if the
higher BMI is associated with a higher amount of FFM. However, if the extra body mass is due to
an increase in fat mass (FM), it may increase the risk of co-morbidities such as obesity, metabolic
syndrome, diabetes, psychological disorders, and cardiovascular diseases (Chatila, Thomashow,
Minai, Criner, & Make, 2008; Franssen & Rochester, 2014; Watz, Waschki, Kirsten, et al., 2009a).
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In the early stages of COPD visceral FM is associated with a decrease in exercise tolerance and
contributes to low grade systemic inflammation, which in turn is associated with mortality in CPD
(Ramachandran, McCusker, Conners, Zuwallack, & Lahiri, 2008; Van den Borst et al, 2012).
Obesity has become increasingly prevalent in CPD and its impact on exercise tolerance, exercise
dyspnoea and prevalence of markers for metabolic syndrome during early stages of COPD also
needs consideration, according to Sava, Maltais, and Poirier (2011). Obesity decreases lung
function and is associated with increased dyspnoea independent of airflow obstruction (Sin,
Jones, & Man, 2002), suggesting that obese patients with CPD may experience more dyspnoea.
Even when obese and overweight patients have less severe airflow obstruction compared to
normal BMI patients, they experience more symptoms (Sava et al., 2010; Vibhuti et al 2007).
According to Monterio et al. (2012), increased FM contributes to muscle pain and fatigue during
exercise, which contributes to decreased physical activity and lower exercise intolerance in CPD.
The decline in PADL and exercise tolerance may cause patients to show symptoms like dyspnoea
during physical exertion at FEV1 levels that are normally considered equal to early stage disease
development. Patients with COPD who were physically inactive were more predisposed to
present with lower FFM percentages and higher FM percentages (Monterio et al., 2012).
Obese CPD patients entering pulmonary rehabilitation programmes commonly have reduced six
minute walk distance but not constant work rate cycling endurance times (Sava et al., 2010),
indicating that increased FM produces greater functional limitations during weight bearing
activities in CPD patients. In this study, normal weight (BMI 21-25 kg.m2), overweight (BMI 25-30
kg.m2) and obese (BMI>30 kg.m2) CPD patients displayed the same magnitude of improvements
in cycling endurance time and six minute walk distance. The differences in six minute walk
distance between high and low BMI were maintained even after exercise rehabilitation, validating
the impact high BMI has on weight bearing activities (Sava et al., 2010).
Exercise training for CPD patients can increase FFM, or delay the decline of FFM due to hypoxia
and deconditioning (Franssen et al., 2004). Fat-free mass is an independent predictor of mortality
in CPD (Schols et al., 2005), which supports the use of body composition assessment when
considering CPD severity, and supports exercise rehabilitation techniques that focus on
19
improvement and preservation of lean mass. In terms of body composition, pulmonary
rehabilitation should aim to increase FFM and decrease FM, while attaining a normal BMI.
2.6. Exercise Testing
Exercise testing is crucial for measuring the physiological impact of CPD on the physical function
of patients. Exercise testing is important for the construction of personalized exercise
rehabilitation programmes for CPD patients to enable the best possible outcomes, and to
measure the effectiveness of exercise rehabilitation programmes. Exercise testing can include
exercise tolerance testing and peripheral muscle strength testing. Methods differ between
researchers and organizations and are dependent on available equipment, accessibility, cost of
administration, and degree of validity and reliability. Below is a summary of common exercise
testing methods used in pulmonary rehabilitation, as reported in the scientific literature.
2.6.1. Aerobic capacity testing
Gas exchange measurement during treadmill exercise, leg ergometry or arm ergometry is still
considered the most accurate way of determining cardiopulmonary ability of early and mid-stage
pulmonary disease individuals. Progressive incremental exercise protocols are normally used
which involves workload increases every 1-2 minutes until volitional exhaustion (American
College of Sports Medicine [ACSM], 2014). Maximal incremental exercise tests are useful in the
evaluation of CPD patients, but require expensive equipment that necessitates regular
maintenance and qualified professionals to supervise testing. The most commonly reported
cardiopulmonary exercise test in CPD is maximal incremental leg ergometry (Bernard et al., 1999;
Franssen et al., 2005; Troosters, Gosselink, & Decramer, 2000; Spruit et al., 2002; Mador et al.,
2011). Cardiopulmonary exercise testing to measure maximal oxygen uptake is a valid and
reliable method of testing aerobic capacity in patients with CPD (American Thoracic Society
[ATS], 2003). Clear guidelines for testing in clinical populations have been outlined by the
American Thoracic Society and the American Heart Association (ATS, 2003; American Heart
Association, 2010).
Constant work rate leg ergometry testing, or cycle endurance test (CET) is often used in
conjunction with incremental leg ergometry testing (Simpson, Killian, McCartney, Stubbing, &
Jones, 1992; Spruit et al., 2002; Mador et al., 2011). For the purpose of measuring cycling
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endurance time, an intensity of 60-80% of peak workload achieved in the maximal incremental
leg ergometer test is selected and patients are encouraged to cycle for as long as they can until
fatigue. Constant load leg ergometry testing has been shown to be a reliable and valid method
for measuring exercise endurance in patients with COPD (van‘t Hul, Gosselink, & Kwakkel, 2003).
Where maximal exercise is not appropriate, submaximal ergometry testing is an alternative
exercise testing method which uses equations to predict VO2max. Typically, it involves 2-4 stages
or 3-4 minutes of continuous exercise with regular increases in workload with each stage. The
YMCA submaximal leg ergometry test is commonly used in clinical populations when
cardiopulmonary exercise testing is either unavailable or unsafe. Heart rates are recorded in the
last minute of each stage, with the aim being to achieve a steady state heart rate (within 6bpm)
(ACSM, 2014). This submaximal ergometry test has been found to be valid and reliable at
predicting peak oxygen uptake, via an extrapolation method of submaximal exercise intensity and
heart rates in a healthy population (Beekley et al., 2004).
The six minute walk test (6MWT) is a self-paced field walking test that has become a popular
method to assess the functional ability of patients with CPD (American Thoracic Society, 2002).
This test measures the distance a person can walk quickly on a flat, hard surface in 6 minutes.
The test requires a 30m walkway but no exercise equipment. The self-paced 6MWT is generally
used to assess patient’s sub-maximal functional capacity. Most patients choose their own
intensity during the test and are allowed to stop and rest when needed. Most PADL are performed
at submaximal levels of exertion so the 6MWT may be a better reflector of the level of functioning
of PADL than maximal incremental tests (Pitta et al., 2005). Although the test is quick and easy
to administer, it does not measure peak oxygen uptake or evaluate the mechanisms of exercise
limitation. For this reason, it has been recommended that the 6MWT be used in conjunction with
maximal incremental exercise tolerance testing (American Thoracic Society, 2002).
Incremental maximal and sub-maximal exercise testing may be used for arm ergometry also. To
determine maximal exercise tolerance in CPD patients using arms, researchers have adopted the
maximal incremental exercise test protocols originally used for leg ergometry and treadmill testing
and used it for arm ergometry. Arm ergometry may be used as an additional testing method to
assess differences in upper and lower limb function in CPD (Owens et al., 1988; Carter, Holiday,
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Stocks, & Tiep, 2003). A review by Janaudis-Ferreira et al. (2011) suggested that arm ergometry
may be the best method for measuring peak supported arm exercise capacity and endurance in
CPD patients as it is easy to standardise and has been demonstrated to be a valid and reliable
test to measure the aerobic capacity.
Unsupported upper limb exercise tests (UULEX), the 6 minute pegboard and ring test (6PBRT)
and the grocery shelving task, are alternative upper limb exercise testing methods (Janaudis-
Ferreira et al., 2011). They require minimal equipment and are easy to administer in a clinical
setting. These tests mimic upper body PADL more than arm ergometry and are useful for
assessing upper body function during upper body PADL tasks. Unsupported upper limb tests
involve self-paced exercise intensity and may not be useful for accurately assessing exercise
capacity.
2.6.2. Peripheral muscle testing
Peripheral muscle strength and endurance testing is important for assessing systemic
manifestations of CPD such as muscle dysfunction. Isokinetic dynamometers are considered the
gold standard when measuring dynamic muscle strength and endurance. It consists of an
adjustable chair constructed next to a swivel able dynamometer with changeable lever arms
allowing testing of different muscles groups at various velocity and speed ranges. The machine
measures muscle force at a set velocity, providing maximal torque values. Muscle strength is
commonly expressed as maximal voluntary contraction. The most commonly tested muscle in
COPD patients is the quadriceps at an angular velocity of 60º.s-1 (Robles et al., 2011).
Handheld dynamometers, which tests the participant’s ability to exert force in a pre-set joint angle
against the assessor, has been used to test upper and lower body strength in CPD (Robles et al.,
2011). Handheld dynamometers are small and portable and have been shown to have excellent
reliability and to correlate with isokinetic dynamometry (r=0.332-0.617, p<0.001) (Whiteley et al.,
2012). They can however, only measure isometric muscle force at various joint angles and cannot
measure strength continuously through the full range of motion (Stark, Walker, Phillips, Fejer, &
Beck, 2011), such as is the case with isokinetic dynamometer testing. They are also dependent
on the strength of the assessor.
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Handgrip force measured using a handgrip dynamometer has been used as an indicator of upper
body strength in CPD (Shah, Nahar, Vaidya, & Salvi, 2013). Low grip strength is related to an
increase risk of multiple chronic diseases and hence premature mortality (Cheung, Nguyen, Au,
Tan, & Kung, 2013). In CPD, handgrip strength may be used as a quick functional measure of
prognosis, as decreased handgrip strength is associated with an increased risk of mortality and
exacerbations (Puhan, Siebeling, Zoller, Muggensturm, & ter Riet, 2012).
One repetition maximum (1RM) is a reliable method of evaluating maximal strength in untrained
middle-aged individuals (Levinger et al., 2009); and has been used to test upper and lower body
strength in CPD patients (Bernard et al., 1999). Repetition maximum is the maximal amount of
weight that can be lifted with one contraction, and can be performed with any machine or free
weights (ACSM, 2014). If it is unsafe to test true 1RM, it can be accurately predicted with an
equation for up to 10 repetitions (Reynolds, Gordon, & Robergs, 2006).
2.7. Exercise Training
The Australian lung foundation (2014) recommends exercise training as an essential part of the
rehabilitation process. Their current evidence-based recommendations are outlined in Table 2-2
below, which incorporates upper and lower body aerobic and strength exercise training. The
ultimate goals of pulmonary rehabilitation are to improve CPD patients’ physical function and
quality of life, increase participation in daily activities, and reduce health care utilization (Troosters,
Casaburi, Gosselink, & Decramer, 2005). A review of the practical recommendations for exercise
training in patients with CPD by Gloeckl, Marinov, and Pitta (2013) summarises the benefits of
exercise training. These benefits can include improvements in quality of life, increased peripheral
muscle strength and endurance, increased aerobic capacity, improved psychological health
profiles, improved balance, reductions in dyspnoea and fatigue perception at rest and during
exercise, decreased hospitalisations, and increased survival rates. The benefits of exercise
training are dependent on the individual goals and training components used in rehabilitation
interventions. New research into the contributions of factors limiting exercise tolerance of CPD
patients may enhance the research focus on examining and establishing specific exercise
rehabilitation guidelines for optimal exercise mode, intensity, frequency and/or volume of training.
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Table 2-2.
Australian Lung Foundation (2014) exercise training guidelines for patients with chronic pulmonary disease.
Mode Intensity Protocol Duration Frequency
Lower
limb
Endurance Training
Walking training
(Ground-based)
80% average speed on 6MWT
75% peak speed on incremental shuttle walk
Dyspnoea rating of 3 (moderate)
Continuous or
interval
30 minutes 4 or 5 times a week that includes 2 or 3
supervised sessions and home exercise
training
Walking training
(Treadmill)
As for ground-based walking training but reduce
speed by 0.5 to 1 kmph until familiar with
treadmill
Continuous or
interval
30 minutes 4 or 5 days a week that includes 2 or 3
supervised sessions and home exercise
training
Stationary cycle
training (if possible)
Dyspnoea rating of 3 (moderate) Continuous or
interval
30 minutes 4 or 5 days a week that includes 2 or 3
supervised sessions and home exercise
training
2) Strength training 10 RM (repetition maximum) 10 reps (1 set) 2 or 3 times a week with at least 1 day rest
between sessions
Upper
limb
Endurance training
Unsupported arm
exercise
Arm ergometry
Determine the weight that the patient can only
lift 15 times
Dyspnoea rating of 2 or 3 (slight or moderate)
15 reps (1 set) 4 or 5 times a week that includes 2 or 3
supervised sessions and home exercise
training
2) Strength training 10 RM (repetition maximum) 10 repetitions
(1 set)
2 or 3 times a week with at least 1 day rest
between sessions
Notes. 6MWT = 6 minute walk test, kmph = kilometres per hour, reps = repetitions, RM = repetition maximum.
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2.7.1. Lower limb benefits of exercise training
Lower limb exercise training in CPD patients has been well-established in pulmonary
rehabilitation due to the impact of lower limb muscle dysfunction on the physical functioning of
these patients (Casabur et al., 1999). Traditionally, exercise rehabilitation for CPD patients was
focused mostly on lower limb aerobic exercises such as cycling and walking (Chester et al., 1977;
Cockcroft, Saunders, & Berry, 1981). Consistent research findings indicating the relative
pronounced lower limb dysfunction apparent in CPD patients gave reason for lower limb strength
training to be introduced as part of the physical rehabilitation of CPD patients. Improvements in
exercise tolerance, such as improved maximum cycling wattage, submaximal cycling endurance
and walking distance, as a result of lower limb strength training have been well documented
(Rochester, 2003). Table 2-3 provides a summary of exercise training interventions studies that
targeted lower limb strength training and exercise capacity conditioning of CPD patients.
The duration of the exercise training protocols ranged from 2-6 months, with a training frequency
of 2-3 days per week. The pre and post exercise training aerobic capacity measures included
maximal incremental leg ergometry testing, CET at 60-80% of peak work rate determined by
incremental leg ergometry, 6MWT, and treadmill endurance walking. Five of the seven studies
used at least two of these lower limb aerobic capacity tests. Leg ergometry testing results are
expressed as peak wattage, VO2max, and VO2peak. Lower limb strength measures utilized in the
studies listed in Table 2-3 includes isokinetic strength and endurance testing of the quadriceps
and hamstrings, 1RM seated leg extension and leg press testing, and quadriceps fatigability
(endurance) measured by twitch force.
Four studies incorporated aerobic training and strength training as part of their exercise protocols.
Two studies included only strength training, while two studies compared aerobic and strength
training protocols. There were marked similarities between the aerobic and strength training
protocols. Aerobic training included leg ergometry and walking (treadmill or ground) or a
combination of the two. All five studies that included leg ergometry determined intensity by
percentage of peak wattage, with the initial wattage ranging from 30-60%. Treadmill walking
speed was determined by 6MWT speed and ground walking speed was at a self-selected
intensity. The majority of strength training protocols included machine weighted exercised,
namely, seated leg press, knee flexion and knee extension. Intensity ranged from 1-3 sets of 8-
25
12 repetitions and training resistance was set at 50-70% of maximal strength. Progression of
exercise intensity was dependent on symptoms (Borg score) and individual improvements, which
were assessed on a weekly basis, with the aim of reaching 70-85% of their maximal strength.
The major findings of the eight studies outlined in table 2-3 were that leg ergometry capacity (peak
wattage, VO2max, and VO2peak) of CPD patients improve statistically significantly with lower limb
aerobic and strength training protocols lasting 8 weeks to 6 months. A longer training programme
duration and the utilization of combined aerobic and strength training exercises generally
produced better effect on walking ability and measures of VO2peak. One study (Simpson et al.,
1992), for example, did not include an aerobic exercise training component (apart from 5 minutes
of warm-up cycling) and reported no significant post-training differences in maximal incremental
leg ergometry wattage. This finding occurred despite the improvements in leg extension 1RM
(44%) and leg press 1RM (16%).
The type of aerobic ability test utilized to measure effect also appeared to impact on the outcome.
Cycle endurance test time and 6MWD for instance improved significantly independent of whether
aerobic training and strength training are used in isolation or in combination. Incremental cycle
ergometer testing requires respondents to manipulate increasingly higher cycle wattage as the
test proceeds while maintaining a pre-determined cycle speed. It is quite possible therefore that
outcome measures such as CET time or 6MWD, which do not require the participant to
manipulate increasingly higher amounts of training loads at a pre-determined speed, are more
prone to show improvements in studies that did not combine aerobic and strength training
protocols.
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Table 2-3.
Summary of the effects of exercise training interventions on lower limb strength and exercise capacity in CPD.
Study Dur/Freq Outcome measures Exercise protocol Training load Progressions Lower limb findings
Simpson
et al.,
1992
n=34
FEV1=18-
96%
3 x pw
8 weeks
Isometric strength:
quadriceps, hamstrings
1RM: single knee
extension and leg press
CET, 6MWT, &
Incremental leg ergometry
Warm up: 5 min low
resistance leg
ergometry
RT: single leg
extension, single
leg press
RT: 3 x 10
reps at 50%
1RM
Increased to
85% 1RM
44% increase in leg extension 1RM and 16% increase
in leg press 1RM (p<0.01)
23% increase max isometric force for quadriceps (240
± 23.6 to 301 ± 25.3 N, p<0.01)
CET significantly improved by 53% (518 ± 69 to 898 ±
95 seconds, p<0.01)
No sig. increases max incremental leg ergometry
capacity
Bernard
et al.,
1999
n=45
GOLD 2-3
12 weeks
3 x pw
Quad strength
Incremental leg ergometry
6MWD
AE: Leg ergometry
RT: leg press &
knee extension
30min
2 x 8-10 reps
60% 1RM
Increased to 3
x 8-10 at 80%
1RM
AE + RT: 8% increase in thigh CSA (160 ± 36 to 171 ±
38 cm2, p<0.0001); 20% increase in quad strength (57
± 20 to 67 ± 21kg, p<0.0001);
12% increase in Wpeak (p<0.05)
21% 6MWD increase (411±81 to 499±68m, p<0.001)
AE: 9% increase in quad strength (51±12 to 56±11kg,
0.05); and a 17% increase in 6MWD (388±78 to 454
±50m, p<0.0005)
19% increase in Wpeak (non-significant)
Clark et
al., 2000
n=26,
GOLD I
12 weeks
2 days
pw
Isotonic strength
Isokinetic strength
Treadmill endurance walk
Incremental leg ergometry
RT: body squat, calf
leg, press knee
flexion, knee
extension
3 x 10 reps
70% Max
70% Max
recalculated at
6 weeks
Quadriceps strength increased by 7.6±7.2kg (p<0.01)
in training group (controls = 0.4±4.8kg)
4205J increase in walking endurance (p<0.001)
Increase in isometric quadriceps work (320J, p<0.05)
Troosters
et al.,
2000
n=34
FEV=41±
16%
6 months
2-3 x pw
6MWT
Isometric quad strength
Incremental leg ergometry
Leg ergometry
treadmill walking
stair climbing
RT: quadriceps
60% Wpeak
6MWTspeed
2min, 1-3
reps
3 x 10 reps
60% 1RM
Increase to
80%
Sig. differences in change between training and
control groups in 6MWD (p=0.01), Wpeak (p=0.003),
VO2max (p=0.02), quadriceps strength ( p=0.004)
Correlation between improvements in 6MWD and
quad strength (r=0.38, p<0.05)
Notes. pw = per week, RM = repetition maximum, CET = cycling endurance time, 6MWT = six minute walk test, 6MWD = six minute walk distance, N = newtons, RT
= resistance training, AE = aerobic exercise, sig. = statistical significance, reps = repetitions, Wpeak = peak wattage, J = joules.
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Table 2-3. Continued.
Study Dur/Freq Outcome measures Exercise protocol Training load Progressions Lower limb findings
Spruit et
al., 2002
AE n = 16
RT n = 14
FEV1=38
±13%
12 weeks
3 x pw
Quadriceps peak torque
Quad, Hamstring force
CET at 70% Wpeak
incremental leg ergometry
6MWT
Walking,
Leg ergometry,
RT: quadriceps,
hamstrings
60% 6MWT
speed
30% Wpeak-
3x8 reps at
70% 1RM
Up to 25 min
at 75% Wpeak
Weekly
increases of
5% 1RM
Sig. increases in 6MWD for RT (38 ± 50 m, p<0.01)
and AE (41 ± 43, p<0.002)
Sig. increase Wpeak for RT (15 ± 16W, p<0.01) and AE
(14 ± 13W, p<0.001)
Sig. increase VO2peak of 89 ± 166 mL.L-1 (p<0.05) for
AE, but not RT (106 ± 253 mL.min-1, p=0.21)
Franssen
et al,
2005
n = 87
GOLD 3
8 weeks
3 days pw
FFM (Bioelectrical
impedance)
Isokinetic quadriceps
strength & endurance
Incremental leg ergometry
Submaximal leg
ergometry
Treadmill walking
Gymnastics
Strength training
50-60%
Wpeak
20min
20min
30min
NS
Based on
subject
improvement
Quadriceps strength and endurance increase of 20%
(p<0.01)
FFM increase of 1.5 ± 0.3kg (p<0.001)
Wpeak increase of 15 ± 2W (p<0.001)
VO2max increase of 137 ± 26mL/min (p<0.01)
Alexander
et al.,
2008
AE+RT
n=10
FEV1=
29.8±13%
8 weeks
2 x pw
1RM seated leg press
lower body strength (chair
stand), 8-foot up and go
6MWT
Treadmill
Leg ergometry
RT: seated leg
press
Combined
aerobic =
20min 1-2 x
12 reps
Increase to 40
min
Based on
RPE 11-13
14% increase in 6MWD (321 ± 32 to 365 ± 105m)
Non sig. increase in leg press 1RM of 2% (106 ± 32kg
to 107 ± 36kg)
Note: p-values not reported.
Mador et
al 2011
n=20
FEV1=
42±13%
pred.
8 weeks
3 x pw
6MWT
Incremental leg ergometry
CET 60-70% Wpeak
Quad strength & twitch
force
Leg ergometry
Treadmill walking
Calisthenics with
and without small
weights
50% Wpeak
80% 6MWT
speed
NS
5-10%
increase when
borg scores
<5
Sig. increases (p<0.05) in 6MWD of 10 ± 15.8% (414
± 134 to 446 ± 128m), Wpeak of 23.1 ± 33.3% (52.9 ±
22.1 to 64.4 ± 26.8W, and CET of 384 ± 352% (6 ± 3
to 24.7 ± 12.5min). All sig. difference compared to
controls.
Improvements in quad strength NS (baseline = 42.8 ±
9.8kg)
Quad fatigability sig. (p<0.05) reduced after training.
No differences between training and control groups.
Notes. pw = per week, RT = resistance training, AE = aerobic exercise, CET = cycling endurance time, Wpeak = peak wattage, 6MWT = six minute walk test, RM =
repetition maximum, 6MWD = six minute walk distance, reps = repetitions, RPE = rating of perceived exertion, sig = statistical significance, FFM = fat-free mass, NS
= not stated.
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The representative outcome measure to monitor improvements in lower limb strength in the eight
studies reported in Table 2-3 was quadriceps strength. Quadriceps strength improved across the
seven studies by 16-44%. Three studies reported on quadriceps endurance but used three
different outcome measures, making it difficult to compare. The one study which provided pre-
and post-quadriceps endurance isokinetic data reported a 20% increase in quadriceps endurance
(Franssen et al., 2005). The information summarized in Table 2-3 provides strong evidence of a
direct relationship between measures of leg strength and the ability to perform cardiovascular
tests that involve the lower limb. This relationship appears to exist independent from stage of
disease development, as the GOLD stage of the participants in all of the studies ranged from mild
or moderate to severe or very severe airflow obstruction.
2.7.2. Upper limb training
To optimize the ability of CPD patients to perform PADLs researchers have also investigated the
impact of upper limb exercise training on upper limb strength and aerobic capacity. Table 2-4
reviews seven upper limb exercise training intervention studies. The duration of the exercise
training protocols ranged from 6-12 weeks with a training frequency of 2-3 days per week, with
the exception of one study that exploited daily exercise training (Ries et al., 1988). Upper limb
aerobic training consists of arm ergometry, unsupported arm exercise, and resistance exercises
targeting the pectorals, deltoids, rhomboids, latissimus dorsi, biceps and triceps muscle groups.
The exercise training protocols are dissimilar across the seven studies making them difficult to
compare. Six of the seven studies included upper limb strength training and five reported on the
strength training outcomes. The strength training protocols across these studies ranged from 1-3
sets of 8-15 repetitions, which is similar to the leg strength training protocols (Table 2-3). Four
studies reported significant improvements in upper body strength using various measures of
strength, namely 1RM testing for arm curl, chest press, lateral pull down and incline bench press,
isometric force for elbow flexion and extension and shoulder flexion and abduction, and handgrip
dynamometry. The one study that reported non-statistically significant improvements in upper
body strength (grip strength) had a small sample size and high standard deviations which would
have impacted on the statistical significance.
Four studies included arm ergometry training, however only two reported post assessment data
(Ries et al., 1988; Gigliotti et al., 2005). Both of these studies reported significant increases in
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arm ergometry endurance time. One study compared arm ergometry and unsupported arm
exercise training, with both training protocols impacting positively on arm ergometry endurance
and measures of perceived dyspnoea and arm fatigue at a given work rate (Gigliotti et al., 2005).
Overall, three of the upper limb exercise training studies reported improvements in dyspnoea at
a given exercise intensity (Ries et al., 1988; Gigliotti et al., 2005; Janaudis-Ferreira et al., 2011).
Improvements after arm exercise training can include increases in arm exercise endurance, upper
body muscle strength, reduced dyspnoea and arm fatigue and improve health-related quality of
life (Janaudis-Ferreira et al., 2011). However, it is unclear how upper body training compares to
lower body training, and which modalities produce the largest improvements in exercise
symptoms, quality of life and performance during PADL. The potential to use arm ergometry to
lengthen or improve the effectiveness of training sessions in an attempt to increase gains in
aerobic capacity remains unclear.
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Table 2-4.
Summary of the effects of exercise training interventions on upper limb strength and exercise capacity in CPD.
Study Dur/Freq Outcome measures Exercise protocol Training load Upper limb findings
Ries et al, 1988
n=45
moderate-severe
COPD
6 weeks
1-2 x
daily
Arm ergometry
UULEX
Arm ergometry
Walking
RT or PNF
RT = 1-2 x 10
reps, 10RM
PNF = 3 x 4-10
reps, 6RM
Number of lifts on unsupported arm exercise test and
endurance time on the arm ergometer increased in both
upper training groups
Simpson et al.,
1992
n=34 FEV1=38%
8 weeks
3 x pw
Isometric handgrip
strength
1RM: arm curl
Warm up: 2 min arm ergometry
RT: arm curl
3 x 10 reps at 50-
85% 1RM
33% increase in arm curl 1RM (p<0.01)
Sig. increase max isometric force for biceps (28 ± 2.6 to 33 ±
3.2 N, p<0.01)
Bernard et al.,
1999
n=45, Gold 2-3
12 weeks
3 x pw
1RM Pectoralis major,
Latissimus dorsi
RT: chest press, lat pull down 30min
2-3 x 8-10 reps
60-80% 1RM
15% increase in pectoralis major strength (64 ± 16 to 73 ±
17kg, p<0.0001); 8% increase in latissimus dorsi strength (53
± 12 to 56 ± 11kg, p<0.05)
Spruit et al., 2002
AE n=16
RT n=14
12 weeks
3 x pw
shoulder abduction, &
elbow flexion force
Handgrip force
Arm ergometry
RT: pectorals, biceps, triceps,
deltoids,
4-9 min
3x8 reps, 70%
1RM
non-sig. increase in handgrip strength for RT (8 ± 15%,
p=0.09) and AE (30 ± 62%, p=0.07)
Gigliotti et al,
2005
n=12
GOLD 2-3
6 weeks
NS
Arm ergometry VO2
Dysnoea/Arm effort
Ventilation
UAE: repeated shoulder abduction
and extension, and ring and peg
board
SAE: Arm ergometry
UAE: as tolerated
SAE: 80% of peak
work rate
A significant increase in arm exercise endurance (p < 0.001)
at a standardized work rate, ventilation, exercise dyspnea,
and arm effort significantly decreased, while the decrease in
IC was significantly less (p < 0.01) post training.
Alexander et al.,
2008
AE n=10
AE+RT n=10
8 weeks
2 x pw
1RM incline bench press
upper body strength (arm
curl)
Arm ergometry
RT: incline bench press, lateral
pulldown, lateral arm raise, triceps
pushdown, upright row, bicep curl
Combined aerobic
= 20-40min
1-2 x 8-15 reps
Non sig. increase in incline bench press 1RM of 5.4% (34 ±
13 to 35 ± 13kg)
Note: p-values not reported.
Janaudis-Ferreira
et al, 2011
n=36
patients with
COPD
6 weeks
3 x pw
Dyspnea during PADL
6PBRT & UULEX
Dyspnoea & Arm fatigue
Isometric hand-held
dynamometer (EF, EE,
SF, SE, SAb, SAd)
RT biceps, triceps, pectoralis
major and minor, latissimus dorsi,
deltoids, and rhomboids
2 x 10-12 reps
10-12 RM
The arm resistance training programme improved arm
function (19.7%) and arm exercise capacity (15.30%) and
arm strength (EF 11.4%, EE 14.8%, SF 10.5%, SAb 13.4%).
Significant improvements in dyspnea during ADL, however no
increase in dyspnea seen with an increase in arm exercise
capacity.
Notes. UULEX = unsupported upper limb exercise test, RT = resistance training, PNF = proprioceptive neuromuscular fascilitation, N = newtons, AE = aerobic exercise, UAE =
unsupported arm exercise, SAE = supported arm exercise,   RM = repetition maximum, 6PBRT = 6min peg board and ring test, PADL = acticities of daily living, EE = elbow flexion, EE
= elbow extension, SF = shoulder flexion, SE = shoulder extension, Sab = shoulder abduction, SAd = shoulder adduction.
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2.8. Conclusion
Research evidence is clear and consistent that disease progression and lower limb dysfunction
impact negatively on aerobic capacity. As the disease increases in severity, the amount of activity
CPD patients are able to do not only decreases, but they also report more symptoms of dyspnoea
during exercise. Upper limb muscle function appears to be less affected than the lower limb and
hence there may be a potential to use arm ergometry to lengthen or improve the effectiveness of
exercise training sessions to speed up or maximise the improvements in aerobic capacity.
Chronic pulmonary disease severity increases with a decline in pulmonary function. Disease
severity can be classified from mild-very severe based on FVC and FEV1 % predicted acquired
through spirometry testing. Research evidence is clear and consistent that disease progression,
reduced levels of physical activity, and lower limb dysfunction impact negatively on aerobic
capacity. There appears to be a downward spiral that exists: as the disease severity increases,
the physical profile of the patient decreases, which in turn results in an increase in symptoms.
A relatively new area of research focuses on the impact of CPD on upper body aerobic capacity,
strength and fibre type changes. The relative importance of this relates to the possibility of
enhanced ability to perform upper body conditioning given upper body muscle function seems to
be less affected than lower limb function, and hence there may be potential to use arm ergometry
to lengthen or improve the effectiveness of training sessions in an attempt to increase gains in
aerobic capacity.
In attempt to enhance the training ability of CPD patients it is important to identify specific exercise
limitations in this population and to assess how much impact each limitation has on the overall
functioning of these individuals. This knowledge will enhance the understanding of the
behavioural and physiologic mechanisms behind the reduction in physical activity, and contribute
to the construction of effective exercise rehabilitation programmes to improve the outcomes of
CPD patients.
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Chapter 3. Method
3.1. Study Design
A cross-sectional research design was used to investigate the within group relationships of
pulmonary, strength, and physiological measures of patients with mild to very severe airflow
obstruction. All participants completed three one hour assessments, with 24 hours minimum
between. Appointment 1 consisted of informed consent, health screening, pulmonary function
testing and IPAQ (International physical activity questionnaire), MRC (Medical Research Council),
and ADL-D (Activity of daily living–Dyspnoea) questionnaires. Appointment 2 included resting
haemodynamics, anthropometric assessment, sub-maximal leg ergometry testing, and grip
strength testing. Appointment 3 included resting haemodynamics, sub-maximal arm ergometry
testing, and isokinetic quadriceps/hamstrings strength and endurance testing. The study protocol
had prior approval of research-ethics from the central lower-north island ethic committee of New
Zealand.
3.2. Participants
Forty-four patients referred by the Palmerston North Hospital Pulmonary clinic to the U-kinetics
exercise and wellness clinic for 12-weeks of exercise-based rehabilitation participated. Written
informed consent was obtained from all participants of the study. The participants had not been
involved in structured exercise training for at least one year prior to participation in the study.
All of the participants had been diagnosed with a chronic pulmonary condition (or a combination)
by a General Practitioner or Respiratory Physician including: chronic bronchitis, emphysema,
COPD, bronchiectasis, asthma, and obstructive sleep apnoea syndrome.
The descriptive and disease severity characteristics of the participants are displayed in Table 3-
1. The study participants included 44 CPD patients, 16 males and 28 females, with a mean age
of 59.8 ± 11.9 years. The mean FEV1% predicted was 54.6 ± 18.3, indicating GOLD stage 2
(moderate CPD). Participant’s FEV1% predicted ranged from 89-22% (mild to very severe airflow
obstruction).
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Table 3-1.
Participant descriptive and disease severity characteristics.
Mean ± SD Range
Age 59.8 ± 11.9 26-72
Weight (kg) 87.3 ± 20.6 41.9-142.1
BMI (kg.m2) 33.2 ± 11.0 18.8-51.9
BF% 30.6 ± 13.1 12.9-60.0
FVC% 70.6 ± 13.2 39-95
FEV1% 54.6 ± 18.3 22-89
GOLD stage 2 1-4
Notes. BMI=body mass index; BF%=body fat percentage, FVC% = forced vital capacity
percentage predicted, FEV1% = forced expiratory flow in one second percentage predicted,
GOLD = GOLD = Global Initiative of Chronic Obstructive Lung Disease.
The number of respondents in each disease severity category, based on the GOLD classification,
is displayed in Figure 4-1. For the purpose of this thesis, disease severity categories were merged
to form two groups, due to the low number of respondents in the mild (n=4) and very severe
categories (n=5). Mild and Moderate CPD stages (GOLD 1-2) were combined to form the “Mild-
Mod” group (n=28) and severe and very severe CPD stages (GOLD 3-4) were combined to form
the “Severe+” group (n=16). The Mild-Mod group included 10 males (35.7%) and 18 females
(64.3%); and the Severe+ group included 6 males (37.5%) and 10 females (62.5%).
Figure 3-1. Number and percentage of participants in disease severity categories based on GOLD
classification.
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3.3. Data Collection
3.3.1. Resting haemodynamics
Resting heart rate and blood pressure were measured after the participant had been in a supine
position for 5 minutes in a quiet room. Resting heart rate was obtained with the values shown on
an electrocardiogram system (custo cardio 100, Custo-Med, Germany). Resting blood pressure
was measured three times manually using a stethoscope and sphygmomometer (DiagnostixTM
720, American Diagnostics Corporation, Hauppauge, NY), and the lowest blood pressure reading
was recorded.
3.3.2. Anthropometric measures
Stature was assessed with shoes removed with a wall mounted stadiometer (model 222, Seca,
Hamburg, Germany). Body mass was measured on a calibrated electronic scale (Tanita,
Cloverdale, Western Australia 6985) with the shoes and as much clothing removed as possible.
Body mass index (BMI) was calculated by dividing body mass (kg) by stature (m) squared. Skin-
fold thickness of six sites (triceps, subscapular, supra-iliac, abdominal, thigh and medial calf) were
measured with Harpenden callipers (CE 0120, BATY International, RH15 9LB, England)
according to the guidelines of the International Society for the Advancement of Kinanthropometry
(Marfell-Jones, Stewart, & Marfell-Jones, 2006). Body fat percentage was calculated using
Yuhasz’s (1974) six-site formula for males [sum of 6 skinfolds x 0.1051 + 2.588], and for females
[(sum of 6 skinfolds x 0.1548 + 3.58].
3.3.3. Sub-maximal exercise tests
Leg ergometry
All participants completed a modified version of the YMCA sub-maximal leg ergometer testing
protocol (ACSM, 2014) for estimation of VO2max. Testing was performed on a leg ergometer
(ec3000e, Custo-med, Germany). The test comprised an unloaded one minute warm-up, followed
by three 4 minute stages. Participants started on 20-30 Watts for the first stage and then power
output was gradually increased with each stage depending on rating of perceived exertion (RPE),
pain and dyspnoea scores, and heart rate and blood pressure responses. Power output was
increased at the end of the 4th minute of each stage if the 3rd and 4th minute heart rates were
within a steady state (± 6 bpm) and no symptom limitations were present. The aim was to reach
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either 70% of the age adjusted maximum heart rate using Karvonen's Formula [(220 - age - resting
heart rate) x 0.7 + resting heart rate], or any symptom limitation according to the ACSM absolute
and relative contra-indications for terminating exercise testing (ACSM, 2014).
Electrocardiography (ECG) was used to monitor heart waveform and rhythm during exercise
testing using the Mason and Likar (1966) modified electrode placement provided by McArdle,
Katch, & Katch (2010). Arm electrodes were positioned medial to the anterior deltoid 1-2cm below
the right and left clavicle and foot electrodes were positioned over the lower ribs.
Power increments were decided by experienced Clinical Exercise Physiologists, based on heart
rate response, Borg scores, physical signs, blood pressure response, and the ECG. Heart rate
was recorded every minute of each stage using the heart rate reading on the ECG. Exercise blood
pressure was manually recorded during the last minute of each stage.
The following equation was used to calculate VO2max [VO2 = ((10.8 x work rate in watts) / body
mass) + 7] (ACSM, 2014).
Arm ergometry
All participants performed an incremental multi-stage sub-maximal arm ergometry test (ACSM,
2014). Testing was performed on a Technogym Arm Ergometer (Top Excite 700, Technogym,
Casena, Italy). Participants sat upright with both feet on the ground and at a distance that their
arms were slightly flexed while undertaking the arm ergometry test. Participants performed one
minute warm-up of unloaded arm cycling, before completing three stages of 3 minutes.
Participants started at 20-30 Watts and power increments were decided by professional judgment
of experienced Clinical Exercise Physiologists, based on heart rate response, Borg scores,
physical signs, and blood pressure response. The aim was to either reach 70% of age-adjusted
maximal heart rates (using Karvonen’s formula as above), a RPE score of higher than 14 or a
wattage equal to or greater than 42% as obtained during the last stage on the leg ergometry
assessment, according to Carter et al. (2003). Test termination points included the presence of
symptom limitation based on the ACSM's (2014) guidelines for early termination.
The following equation was used to calculate VO2max [VO2 = ((18 x work rate in watts) / body
mass) + 3.5] (ACSM, 2007). If peak wattage beyond 42% of leg ergometry wattage were required
for subjects to reach the same maximum heart rates as obtained during leg ergometry, the test
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continued beyond 3 stages until they reached the required heart rate, or the clients requested to
stop.
Dyspnoea, fatigue and RPE scores
Dyspnoea was measured during each stage of arm and leg ergometry using the Borg dyspnoea
scale (Borg, 1998). Perceived exertion was measured using the Borg RPE scale. Perceived arm
and leg fatigue was recorded using the Borg CR-10 scale (Borg, 1998). Subjects were instructed
to report a number describing their perception of limb fatigue during each stage of respectively
arm and leg ergometry. The Borg CR-10 scale is a general intensity scale with ratings from 0-12
that has previously been used to measure extremity pain/fatigue during exercise (Carter et al.,
2003).
3.3.4. Pulmonary function testing
Spirometry was performed in order to verify the degree of airway obstruction, with consideration
to the ratio FEV1/FVC, so that participants could be classified into mild (FEV1 ≥ 80% predicted),
moderate (predicted 50% ≤ FEV1 < 80%), severe (predicted 30% ≤ FEV1 < 50%) and very severe
(predicted FEV1 < 30%) obstruction categories (GOLD, 2014). Spirometry was performed using
a hand-held spirometer (EasyOne, nnd Medizintech AG, 8005 Zurich, Switzerland), which was
calibrated prior to each test with a 3L syringe. Participants performed the FEV1 and FVC
manoeuvre according to the American Thoracic Society guidelines (ATS, 2005). The participants
sat in an upright position with both feet on the floor wearing a nose peg when performing the test,
and were instructed to breathe in as deeply as they could, seal their lips around the mouthpiece,
and blow out as hard, fast and as long as possible. Subjects performed three attempts and the
best attempt was recorded.
3.3.5. Peripheral muscle strength testing
Upper body
Upper limb strength was measured by grip strength using a Baseline Hydraulic Hand
Dynamometer (Irvington New York, 10533 U.S.A). Two attempts were performed on each side
for familiarization and highest reading was recorded. The grip strength test started with the arm
in shoulder abduction of 90 degrees, with the elbow in full extension (00 of flexion). The subject
was instructed to grip the hand dynamometer as hard as they could, lower the arm down to the
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side of the body squeezing the tool with a maximum effort. The dynamometer was reset to zero
prior to each reading.
Lower body
Lower limb strength and endurance was measured by knee flexion and extension using an
Isokinetic muscle dynamometer (HUMAC norm, model 502140, Computer Sports Medicine, Inc.,
Stoughton, MA 02072, USA). The dynamometer was calibrated according to standard settings
outlined by the user manual with the axis of rotation in line with subject’s femoral epicondyles.
The dynamometer was corrected for gravity. Range of motion (ROM) was set to at least 90°.
Subjects completed one trial set of 5 repetitions at 60 and 180°.s-1 for familiarization and then one
set of 5 repetitions at 60°.s-1 and one set of 15 repetitions as fast as possible at 180°.s-1. Each set
was separated by a 60 second rest interval, which has been found to be an adequate rest period
during isokinetic testing to avoid fatigue (Parcell, Sawyer, Tricoli, & Chinevere, 2002). Subjects
were instructed to flex and extend their knee as hard and as fast as they could for the full duration
of the test. This quadriceps/hamstring strength and endurance testing protocol has been used on
healthy, inactive, elderly individuals (Malliou et al., 2003).
3.3.6. Dyspnoea
All subjects completed the MRC scale (Fletcher, Elmes, Fairbairn, & Wood, 1959) for the purpose
of determining severity of dyspnoea and stage of disease. All subjects completed the Activity of
Daily Living Dyspnoea (ADL-D) scale (Yoza, Ariyoshi, Honda, Taniguchi, & Senjyu, 2009), which
contains 15 items for assessing activity of daily living in patients with CPD. Subjects provide a
dyspnoea score of 4 (not at all) to 0 (maximal) for each item, with a lower score indicating more
severe dyspnoea.
3.3.7. International Physical Activity Questionnaire (IPAQ)
Current Physical Activities of daily living (PADL) were assessed using the International Physical
Activity Questionnaire (IPAQ) – Long Form. The IPAQ has 4 distinct PADL groupings,
distinguishing between job-related, transport, domestic and recreational (sport and leisure) PADL.
The IPAQ captures participation according to days and minutes of activity and segregates
between walking, moderate and vigorous activity by multiplying the various activity minutes with
a MET factor (8 METs for vigorous activity; 4 METs for moderate activity and 3.3 METs for
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walking). The questionnaire provides a total activity METs per minute score as well as individual
METs per minute scores for each of the four PADL groups. The IPAQ is currently considered the
gold standard of physical activity questionnaires, which has acceptable validity when assessing
levels and patterns of physical activity in adults (Hagströmer, Oja, & Sjöström, 2006).
A comprehensive and detailed interview was used in conjunction with the IPAQ to determine the
amount of upper and lower body PADL participants performed on a daily basis. This was done in
order to compare the impact of daily upper and lower body physical activities on aerobic capacity
(arm and leg ergometry) and measures of arm and leg strength.
3.4. Data Analysis
Statistical analyses were performed using STATISTICA (Version 7.0) and SPSS (Version 22).
Descriptive statistics are presented as means ± standard deviation. The data set presented with
normal distribution. Accordingly, a total of 8 statistical procedures were conducted including t-
tests, partial correlations, ANOVA, multiple linear regressions and a binary logistical regression
as follows:
Between group differences regarding anthropometric, PADL, aerobic and strength values were
analysed using unpaired t-tests for disease severity groups and gender.
A factorial ANOVA was conducted to explore the independent relationships of PADL and GOLD
stage with measures of arm and leg aerobic capacity and strength. The Tukey’s post-hoc test
was used to determine sub-group significance. Wilks Lambda and ETA2 analysis was used to
determine the combined and individual contributions of measures of PADL (type and volume) and
FEV1 to arm and leg ergometry capacity of patients with CPD.
Partial correlations were performed - controlling for age, gender, and BF% - to assess
relationships between measures of aerobic capacity (upper and lower body arm ergometry
capacity), measures of strength (grip and isokinetic quadriceps and hamstrings), pulmonary
function and physical activity (total activity and upper and lower body activity). The aim of the
partial correlations were to determine whether the ANOVA finding, that physical activity negates
the detrimental effect of disease development on certain measures of strength and arm aerobic
capacity, will sustain after statistical control for the influence of external variables such as BF%,
gender, and age.
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Two multiple linear regressions were conducted to determine if peak arm and leg ergometry
wattage could be predicted with quadriceps strength, grip strength and FEV1. A check for multi-
collinearity was completed and variables with r < 30 and > 90 were excluded. This analysis
provided more specific information about individual contributions. A binary logistic regression
analysis was used to examine the predictability of upper body function (arm ergometry) by
quadriceps strength.
For the purpose of the ANOVA and the binary logistical regression statistical analyses the
respondents were placed in groups.  For the ANOVA respondents were grouped according to
“high” and “low” regarding participation in total PADLs and FEV1%. For total PADL level was split
at the 50th percentile and FEV1% was split according to GOLD groups at 50% predicted (Mild-
moderate = low, and severe-very severe = high). The physical activity levels of the participants
was generally low and there were only 16 respondents with severe and very severe COPD (FEV1
<50%). The 50th percentile of the group distribution was henceforth selected for PADLS and FEV1
to ensure enough participants in the groups. For the multiple linear and binary logistical
regressions participants were grouped for each of the variables used into relative “high” and “low”
categories. Peak arm and leg ergometry wattage, quadriceps strength, and grip strength were
split at the 60th percentile, while upper and lower body PADLs, and FEV1% were again split at
the 50th percentile of the group distribution. Grouping at the 60th percentile are generally
recommended for binary and regression analysis because the aim is to distinguish predictability
of either poor or good performers (Thomas, Nelson, & Silverman, 2012).
3.4.1. Participant groups for further analysis:
For the statistical analyses, the participants were not grouped according to sex for three reasons.
Firstly, the numbers of male and female participants were similar in the two disease severity
groups. Secondly, the thesis aimed to investigate the influence of disease severity, rather than
gender, on arm and leg ergometry capacity. Finally, although one could argue that males and
females may respond differently during exercise and have different relationships between the
variables measured, the sample size was too small to split the groups further.
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Chapter 4. Results
The results reported below have been organised into themes relating to the outcome measures.
Firstly, comparisons of male and female participants are reported. The results then split into
sections regarding participant descriptive/anthropometric characteristics, disease severity,
aerobic, strength and physical activity measures. Each section reports the t-test, and ANOVA
statistics of the specified variable groups. These sections are then followed by a partial correlation
of strength, aerobic and physical activity variables. The chapter concludes with the reporting of
the prediction statistical procedures (multiple linear regression and binary regression analyses)
that were conducted.
4.1. Comparison of Male and Female Participants
4.1.1. Descriptive/anthropometric measures
A comparison of descriptive data for male and female CPD patients is displayed in Table 4-1.
Body fat percentage was 15.9% higher in females compared to males (p<0.001), while body mass
was comparable between males and females. There were no significant differences between
males and females for age or BMI.
Table 4-1.
Comparison of males and female participants for descriptive and anthropometric data.
Total (n=44)
± SD
Male (n=16)
± SD
Female (n=28)
± SD
t-value p-value
Age 59.8 ± 11.9 63.50 ± 9.2 57.68 ± 12.9 1.59 0.12
Body mass
(kg) 87.3 ± 20.6 89.45 ± 13.9 86.04 ± 23.7 0.53 0.60
BMI 33.15 ± 11.0 29.69 ± 4.1 35.13 ± 13.1 -1.61 0.11
BF% 30.56 ± 13.1 20.41 ± 7.7 36.36 ± 12.0 -4.77 <0.001
Note. BMI=body mass index, BF%=body fat percentage.
4.1.2. Disease severity
There were no significant differences between males and females for any of the disease severity
measures (Table 4-2).
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Table 4-2.
Comparison of males and female participants for disease severity measures.
Total (n=44)
± SD
Male (n=16)
± SD
Female (n=28)
± SD
t-value p-value
FVC% 70.6 ± 13.2 71.1 ± 13.0 70.4 ± 13.6 0.18 0.86
FEV1% 54.6 ± 18.3 50.6 ± 19.7 55.2 ± 17.8F -0.27 0.78
MRC Grade 2.0 ± 0.9 2.1 ± 0.9 2.3 ± 0.9 -0.72 0.48
Note. FVC% = forced vital capacity percentage predicted, FEV1% = forced expiratory flow in
one second percentage predicted, MRC = Medical Research Council.
4.1.3. Peripheral muscle strength
Males displayed significantly higher grip strength, quadriceps strength and hamstring strength
(p<0.001) compared to female participants (Table 4-3). Quadriceps and hamstrings endurance
were comparable for males and females.
Table 4-3.
Comparison of males and female participants for peripheral strength measures.
Total (n=44)
± SD
Male (n=16)
± SD
Female (n=28)
± SD
t-value p-value
Grip strength (kg) 30.9 ± 10.4 41.1 ± 8.6 25.1 ± 5.8 7.37 <0.001
Quad strength (Nm) 103.7 ± 35.0 129.4 ± 24.6 89.0 ± 31.6 4.40 <0.001
Ham strength (Nm) 53.1 ± 19.5 66.94 ± 16.0 45.2 ± 16.9 4.12 <0.001
Quad endur. (Nm) 88.4 ± 14.1 88.9 ± 12.3 88.2 ± 15.3 0.16 0.87
Hamstring endur. (Nm) 98.7 ±30.9 90.1 ± 16.8 103.6 ± 36.0 -1.41 0.17
Note. Quad endur. = quadriceps endurance, Hamstring endur. = hamstring endurance.
4.1.4. Arm and leg ergometry
The total group mean for arm ergometry VO2peak was comparable to the group mean VO2peak for
leg ergometry (Table 4-4). There were significant differences between males and females for
peak arm ergometry wattage (p=0.01), peak leg ergometry wattage (p=0.02), and leg ergometry
VO2peak (p=0.03). Male leg ergometry VO2peak was significantly higher than females (p=0.03),
however no difference was seen between males and females for arm ergometry VO2peak. No
statistically significant differences were seen between sexes for either arm or leg ergometry pain
scores.
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Table 4-4.
Comparison of males and female participants for arm and leg ergometry measures.
4.1.5. Physical activities of daily living
Male’s total physical activity level was 12.6% higher than females. Males reported a significantly
(p=0.02) higher level of vigorous physical activity and walking activity (p=0.05) than females
(Table 4-5).
Table 4-5.
Comparison of males and female participants for physical activity of daily living measures.
Total (n=44)
± SD
Male (n=16)
± SD
Female (n=28)
± SD
t-value p-value
Total activity* 3074 ± 3320 3342 ± 4586 2921 ± 2408 0.40 0.69
Vigorous activity* 313 ± 1042 798 ± 1643 36 ± 103 2.47 0.02
Moderate activity* 2242 ± 2283 1743 ± 2269 25278 ± 2281 -1.10 0.28
Walking activity* 524 ± 762 815 ± 1149 358 ± 334 1.98 0.05
Note. *Activity measured in MET (metabolic equivalents) minutes/week.
4.2. Participant’s Descriptive/Anthropometric Characteristics
4.2.1. GOLD group comparison
Table 4-6 provides data of the comparisons between the two CPD groups (mild-moderate vs.
severe+) for the descriptive/anthropometric data. Although the two groups mean age differed by
7 years and body mass and the mild-mod group was on average 12.3kg heavier, these differences
were not significant (p=0.06 and p=0.05, respectively). There were no statistically significant
differences (p>0.05) between the two groups in terms of any of the anthropometric variables.
Total (n=44)
± SD
Male (n=16)
± SD
Female (n=28)
± SD
t-value p-value
Leg VO2peak 21.8 ± 5.9 24.3 ± 6.7 20.4 ± 4.9 2.23 0.03
Leg Wattpeak 49.3 ± 19.1 57.8 ± 20.2 44.5 ± 17.0 2.24 0.02
Leg Painpeak 3.3 ± 1.8 2.8 ± 1.6 3.6 ± 1.9 -1.41 0.17
Arm VO2peak 21.6 ± 6.3 21.67 ± 6.6 21.5 ± 6.2 0.06 0.95
Arm Wattpeak 38.9 ± 11.7 45.0 ± 12.8 35.4 ± 9.6 2.84 0.01
Arm Painpeak 3.3 ± 1.5 3.34 ± 1.6 3.3 ± 1.5 0.17 0.86
Note. VO2peak = peak oxygen consumption (mL/kg.min), Wattpeak = peak ergometry wattage,
Painpeak = peak pain score during ergometry.
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Table 4-6.
Comparison of GOLD groups for descriptive and anthropometric data.
Total (n=44)
± SD
Mild-Moderate
(n=28)
± SD
Severe+ (n=16)
± SD
t-value p-value
Age 59.8 ± 11.9 57.3 ± 13.5 64.3 ± 6.7 1.93 0.06
Body mass (kg) 87.3 ± 20.6 91.8 ± 22.0 79.4 ± 15.5 -1.98 0.05
BMI 33.2 ± 11.0 35.2 ± 12.8 29.7 ± 5.4 -1.63 0.11
BF% 30.6 ± 13.1 32.3 ± 14.0 27.5 ± 11.0 -1.18 0.24
Note. BMI = body mass index, BF% = body fat percentage.
4.2.2. Relationship of CPD stage and physical activities of daily living with descriptive
and anthropometric data
Results of a factorial ANOVA, where the dependent and independent relationships of disease
severity and physical activity volume were compared with participant characteristics, are reported
in Table 4-7. No statistically significant differences were found between any of the physical activity
and disease severity groups for participant characteristic data. It is important to note the
comparative large standard deviation of group a (age = 16.22) and group b (body mass = 29.02)
due to two outliers which ended up in those groups. These high standard deviations, as well as
the small sample sizes had an impact on statistical significance.
Table 4-7.
Combined and individual relationships of CPD stage and total PADL with descriptive and
anthropometric data, as determined with a factorial ANOVA.
CPD Stage
PADL
(min/week)
Mild-Moderate Severe +
X SD X SD
Age Low a 55.7 16.2 c 64.5 5.6
High b 59.3 9.6 d 64.0 8.1
Body Mass Low a 95.7 14.6 c 77.4 16.3
High b 86.5 29.0 d 81.5 15.6
BMI Low a 37.7 14.4 c 28.0 4.8
High b 31.8 10.0 d 31.3 5.6
Body fat % Low a 35.2 14.4 c 24.4 8.5
High b 28.5 13.1 d 30.6 12.9
Note. Group a = mild-moderate CPD and low PADL level (n= 16), group b = mild-moderate CPD
and high PADL level (n= 12), group c = severe+ CPD and low PADL level (n= 8), and group d =
severe+ CPD and high PADL level (n= 8).
The F-ratio, p-values, ETA2, and Wilks Lambda scores of the factorial ANOVA for the descriptive
and anthropometric data are reported in Table 4-8. The Eta2 calculations indicated that CPD
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disease stage shows larger (non-significant) independent contributions than total PADL minutes
to the variances of age, body mass, BMI, body fat percentage.
The Wilks Lambda scores (Table 4-8) indicated that the two independent variables in combination
(CPD stage and total PADL minutes) explained small portions of the variances in age (100-
90.3=9.7%), body mass (100-87.9=12.1%), BMI (100-88.7=11.3%), and body fat percentage
(100-90.4=9.6%).
Table 4-8.
The f-ratio, p-values, ETA2 and Wilks Lambda scores of the factorial ANOVA investigating the
relationships of CPD stage and total PADL with descriptive and anthropometric data.
Dependent variables ANOVA groups F-ratio p-values Eta2 Wilks Lambda
Age CPD stage
Total PADL
Combined
3.326
0.181
1.428
0.076
0.673
0.249
27.4
6.39
9.67
90.3
Body Mass CPD stage
Total PADL
Combined
3.438
0.173
1.836
0.071
0.679
0.156
27.5
6.17
12.1
87.9
BMI CPD stage
Total PADL
Combined
2.267
0.137
1.701
0.140
0.713
0.182
22.4
5.51
11.3
88.7
Body fat % CPD stage
Total PADL
Combined
1.143
0.004
1.411
0.292
0.951
0.254
16.1
0.94
9.57
90.4
4.3. Disease Severity
4.3.1. GOLD group comparison
The mean FEV1% was 54.64±18.27, indicating GOLD stage 2 (moderate COPD), ranging from
22-89% (very severe to mild CPD). The groups showed statistically significant differences with
regard to FVC% (p<0.002) and FEV1% (p<0.0001), and MRC grade (p<0.003) (Table 4-9).
Table 4-9.
Comparison of GOLD groups and disease severity measures.
Total (n=44)
X ± SD
Mild-Moderate (n=28)
X ± SD
Severe+ (n=16)
X ± SD
t-value p-value
FVC% 70.6 ± 13.2 75.18 ± 11.4 62.7 ± 12.6 -3.36 0.002
FEV1% 54.6 ± 18.3 65.93 ± 10.7 34.9 ± 9.8 -9.54 0.0001
MRC
Grade 2.4 ± 0.8 1.9 ± 0.7* 2.8 ± 0.9 3.19 0.003
Note. FVC% = forced vital capacity percentage predicted, FEV1% = forced expiratory flow in
one second percentage predicted, MRC = Medical Research Council.
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4.3.2. Relationship of CPD stage and physical activities of daily living with other
measures of disease severity
Statistically significant differences were evident with the MRC grade and FVC% predicted (Table
4-10). The ANOVA split participants into four groups according to physical activity volume and
GOLD stages. Group a, refers to participants with mild-moderate CPD and low physical activity
levels. Group b refers to participants with mild-moderate CPD and high physical activity levels.
Group c includes participants with severe CPD and low physical activity levels. Group d refers to
participants with severe CPD and high physical activity levels.
The Tukey post hoc test (Table 4-10) demonstrated that groups a (low PA and mild-moderate
stage) and b (high PA but mild-moderate CPD stage) displayed better MRC grade scores than
groups c (low PA and severe to very severe CPD stage), with a set p-value of <0.05. Group a
also presented with a statistically significantly higher mean FVC% when compared to groups c
and d (p<0.05).
Table 4-10.
Combined and individual relationships of CPD stage and total PADL with other makers of
disease severity, as determined with a factorial ANOVA.
CPD Stage
Total PADL
(min/week)
Mild-Moderate Severe +
X SD X SD
MRC Grade Low a 1.9c 0.6 c 3.1 a b 0.83
High b 2.9c 0.9 d 2.4 0.74
ADL-D Low a 52.0 7.2 c 49.9 4.91
High b 49.9 7.4 d 50.4 4.67
FVC% Low a 77.4 c d 13.6 c 62.1a 12.3
High b 72.3 13.2 d 63.1a 13.8
Note. MRC = Medical Research Council, ADL-D = dyspnoea during activities of daily living,
FVC% = forced vital capacity percentage predicted.
Group a = mild-moderate CPD and low PADL level (n= 16), group b = mild-moderate CPD and
high PADL level (n= 12), group c = severe+ CPD and low PADL level (n= 8), and group d =
severe+ CPD and high PADL level (n= 8).
a indicates statistical significant (p<0.05) difference from group a, b indicates statistical significant
(p<0.05) difference from group b, c indicates statistical significant (p<0.05) difference from group
c, and d indicates statistical significant (p<0.05) difference from group, as found with the Tukey
post-hoc test.
The data in Table 4-11 indicated that CPD stage contributed independently and significantly to
the variances of FVC% predicted (44.5%; p=0.003), MRC grade (43.3%; p=0.003) and peak leg
ergometry wattage (31.4%; p=0.035). Total activity did not contribute significantly to the variances
of any of the dependent variables. As a combination, CPD stage and Total Activity contributes
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statistically significantly to the variances of FVC% (23.6%; p = 0.012) and MRC grade (27.4%;
p=0.005).
Table 4-11.
The f-ratio, p-values, ETA2 and Wilks Lambda scores of the factorial ANOVA investigating the
relationship of CPD stage and total PADL with other markers of disease severity in CPD
patients.
Dependent variables ANOVA groups F-ratio p-values Eta2 Wilks Lambda
FVC% CPD stage
Total PADL
Combined
10.356
0.282
4.121
0.003
0.598
0.012
44.5
7.33
23.6
76.4
MRC Grade CPD stage
Total PADL
Combined
10.257
1.266
5.030
0.003
0.267
0.005
43.1
15.2
27.4
72.6
ADL-D CPD stage
Total PADL
Combined
0.159
0.143
0.306
0.693
0.708
0.821
6.23
5.90
2.24
97.6
Notes. MRC = Medical Research Council, ADL-D = dyspnoea during activities of daily living,
FVC% = forced vital capacity percentage predicted.
4.4. Peripheral Muscle Strength
4.4.1. GOLD group comparison
The mean quadriceps strength, as measured by peak torque, for the total group was 103.67 ±
34.99 Nm, and mean hamstring strength was 53.10 ± 19.47 Nm for the total group. Statistically
significant differences were found between the two GOLD groups for quadriceps strength and
hamstrings strength (p<0.05). No differences existed between GOLD groups for grip strength,
quadriceps endurance or hamstrings endurance.
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Table 4-12.
Comparison of GOLD groups for peripheral strength measures.
Total (n=44)
± SD
Mild-Moderate
(n=28)
± SD
Severe+
(n=16)
± SD
t-value p-value
Grip strength
(kg) 30.9 ± 10.4 31.8 ± 10.6 29.4 ± 10.3 -0.73 0.47
Quad strength
(Nm) 103.7 ± 35.0 111.3 ± 37.7 90.3 ± 25.6 -1.97 0.05
Ham strength
(Nm) 53.1 ± 19.5 57.5 ± 21.0 45.4 ± 13.8 -2.06 0.04
Quad endur.
(Nm)
88.4 ± 14.1 87.2 ± 14.1 90.5 ± 14.4 0.73 0.47
Hamstring
endur. (Nm) 98.7 ± 30.9 96.3 ± 25.2 102.8 ± 39.7 0.67 0.50
Note. Quad endur. = quadriceps endurance, Hamstring endur. = hamstring endurance.
4.4.2. Relationship of CPD stage and physical activities of daily living with peripheral
muscle strength
Results of a factorial ANOVA, where the dependent and independent relationships of disease
severity and total PADL participation were compared with peripheral muscle strength measures,
are reported in Table 4-13. No statistically significant differences were found between any of the
physical activity and disease severity groups for the peripheral muscle strength data.
Table 4-13.
Combined and individual relationships of CPD stage and total PADL living with peripheral
muscle strength, as determined with a factorial ANOVA.
CPD Stage
PADL
(min/week)
Mild-Moderate Severe +
X SD X SD
Grip strength Low a 33.0 9.7 c 32.6 13.1
High b 30.2 11.9 d 26.2 5.5
Quad strength Low a 116.9 38.0 c 98.1 33.8
High b 103.8 37.6 d 82.6 11.2
Hamstring strength Low a 61.5 21.2 c 44.5 18.1
High b 52.2 20.4 d 46.3 9.0
Quad endurance Low a 89.4 10.7 c 93.9 17.9
High b 84.3 17.7 d 87.1 10.0
Hamstring endurance Low a 94.6 12.7 c 119.3 48.7
High b 98.7 36.4 d 86.4 19.5
Note. Group a = mild-moderate CPD and low PADL level (n= 16), group b = mild-moderate CPD
and high PADL level (n= 12), group c = severe+ CPD and low PADL level (n= 8), and group d =
severe+ CPD and high PADL level (n= 8).
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The F-ratio, p-values, ETA2, and Wilks Lambda scores of the factorial ANOVA for the peripheral
muscle strength data are reported in Table 4-14. The Eta2 calculations indicated that CPD disease
stage showed larger (non-significant) independent contributions than total PADL minutes to the
variances of quadriceps strength and hamstrings strength. Total activity showed larger (non-
significant) independent contributions than CPD stage to the variances of grip strength and
quadriceps and hamstring endurance.
The Wilks Lambda scores (reported in Table 4-14) indicated that the two independent variables
in combination (CPD stage and total activity minutes) explains small portions of the variances in
grip strength (100-94.1=3.9%), quadriceps strength (100-87.5=12.5%), hamstrings strength (100-
87.1=12.9%), quadriceps endurance (100-94.5=5.5%) and hamstrings endurance (100-
88.1=11.9%).
Table 4-14.
The f-ratio, p-values, ETA2 and Wilks Lambda scores of the factorial ANOVA investigating the
relationships of CPD stage and total PADL with peripheral muscle strength measures.
Dependent variables ANOVA groups F-ratio p-values Eta2 Wilks Lambda
Grip strength CPD stage
Total PADL
Combined
0.441
1.957
0.841
0.511
0.170
0.479
10.2
21.5
5.94
94.1
Quad strength CPD stage
Total PADL
Combined
3.514
1.779
1.906
0.068
0.190
0.144
27.7
19.7
12.5
87.5
Hamstring strength CPD stage
Total PADL
Combined
3.753
0.405
1.978
0.059
0.528
0.133
28.6
9.39
12.9
87.1
Quad endurance CPD stage
Total PADL
Combined
0.658
1.745
0.770
0.422
0.194
0.518
12.5
20.3
5.46
94.5
Hamstring endurance CPD stage
Total PADL
Combined
0.430
2.321
1.795
0.516
0.135
0.164
9.74
22.6
11.9
88.1
4.5. Arm and Leg Ergometry
4.5.1. GOLD group comparisons
Participants with mild-moderate CPD demonstrated significantly higher (28%) peak leg ergometry
wattage compared to the severe CPD group (p=0.03). The mild-moderate CPD group
demonstrated a 17% higher peak arm ergometry wattage, which was close to meeting statistical
significance (p=0.07). In addition, the leg pain scores reported during the ergometry testing were
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20% greater for those with mild-moderate disease compared to severe disease, however the
difference was not statistically significant (p<0.08). Arm pain scores were 23% higher in the mild-
moderate CPD group, compared to the severe group (p=0.13).
Table 4-15.
Comparison of GOLD groups for arm and leg ergometery outcomes.
4.5.2. Relationship of CPD stage and physical activities of daily living and arm and leg
ergometry
Results of a factorial ANOVA, where the dependent and independent relationships of disease
severity and physical activity volume were compared with arm and leg ergometry outcome
measures, are reported in Table 4-15. No statistically significant differences were found between
the physical activity and disease severity groups for any of the arm and leg ergometry outcome
measures.
Total (n=44)
± SD
Mild-Moderate (n=28)
± SD
Severe (n=16)
± SD
t-
value
p-
value
Leg
VO2peak
21.8 ± 5.9 22.8 ± 6.4 20.1 ± 4.5 -1.50 0.14
Leg
Wattpeak
49.3 ± 19.1 54.1 ± 21.0 40.9 ± 11.9 -2.30 0.03
Leg
Painpeak
3.3 ± 1.8 3.3 ± 1.7 2.7 ± 1.8 -1.78 0.03
Arm
VO2peak
21.6 ± 6.3 22.4 ± 6.5 20.1 ± 5.9 -1.16 0.07
Arm
Wattpeak
38.9 ± 11.7 41.3 ± 11.8 34.7 ± 8.3 -1.84 0.08
Arm
Painpeak
3.3 ± 1.5 3.6 ± 1.6 2.8 ± 1.4 -1.54 0.13
Note. VO2peak = estimated peak VO2 (ml/kg/min), Wattpeak = peak ergometry wattage, Painpeak =
peak pain during ergometry.
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Table 4-16.
Combined and individual relationships of CPD stage and total PADL with arm and leg ergometry
capacity, as determined with a factorial ANOVA.
CPD Stage
Total PADL
(min/week)
Mild-Moderate Severe +
X SD X SD
Leg Wattpeak Low a 58.8 20.0 c 41.9 14.6
High b 47.9 21.4 d 40.0 9.3
Leg VO2peak Low a 22.4 4.7 c 19.4 5.2
High b 23.4 8.3 d 20.8 4.0
Leg RPEpeak Low a 12.8 1.6 c 12.9 1.7
High b 12.7 2.2 d 12.3 0.9
Leg Dysppeak Low a 2.9 1.2 c 3.7 1.3
High b 2.7 0.8 d 2.9 1.2
Leg Painpeak Low a 3.7 1.3 c 2.6 2.2
High b 3.6 2.3 d 2.8 1.6
Arm Wattpeak Low a 42.8 10.2 c 33.1 9.6
High b 39.8 15.9 d 36.3 6.9
Arm VO2peak Low a 21.7 5.6 c 17.7 5.9
High b 23.4 7.6 d 22.6 5.0
Arm RPEpeak Low a 12.7 1.7 c 13.1 1.0
High b 12.6 1.6 d 11.5 1.2
Arm Dysppeak Low a 2.4 0.7 c 2.5 1.5
High b 2.4 1.2 d 2.2 1.3
Arm Painpeak Low a 3.7 1.6 c 3.2 1.5
High b 3.4 1.6 d 2.5 1.2
Notes. Wattpeak = peak ergometry wattage, VO2peak = estimated peak VO2 (ml/kg/min), RPEpeak =
peak rating of perceived exertion, Dysppeak = peak dyspnoea, Painpeak = peak pain during
ergometry. Group a = mild-moderate CPD and low PADL level (n= 16), group b = mild-moderate
CPD and high PADL level (n= 12), group c = severe+ CPD and low PADL level (n= 8), and group
d = severe+ CPD and high PADL level (n= 8).
The F-ratio, p-values, ETA2, and Wilks Lambda scores of the factorial ANOVA for the arm and
leg ergometry data are reported in Table 4-16. The Eta2 calculations indicated that CPD disease
stage displayed larger (non-significant) contributions than overall physical activity minutes to the
variances of peak leg ergometry wattage, peak leg ergometry VO2, peak leg pain, peak arm
ergometry wattage, and peak arm pain. Total activity displayed larger (non-significant)
independent contributions than CPD stage to the variances of peak leg ergometry RPE score,
peak arm ergometry VO2, and peak arm ergometry RPE and dyspnoea scores.
The Wilks Lambda scores (reported in table 4-16) indicated that the two independent variables in
combination (CPD stage and total activity minutes) explain small portions of the variances of peak
leg ergometry wattage (100-83.6=16.7%) and peak arm ergometry RPE (100-87.9=12.3%), and
less than 10% of the variances of the other arm and leg ergometry variables.
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Table 4-17.
The f-ratio, p-values, ETA2 and Wilks Lambda scores of the factorial ANOVA investigating the
relationships of CPD stage and total PADL with arm and leg ergometry capacity in CPD
patients.
Dependent variables ANOVA groups F-ratio p-values Eta2 Wilks Lambda
Leg Wattpeak CPD stage
Overall Act
Combined
4.725
1.242
2.622
0.035
0.272
0.064
31.4
16.1
16.4
83.6
Leg VO2peak CPD stage
Total PADL
Combined
2.247
0.395
0.852
0.142
0.533
0.474
22.9
9.63
6.01
94.0
Leg RPEpeak CPD stage
Total PADL
Combined
0.131
0.444
0.228
0.719
0.509
0.877
5.57
10.4
1.68
98.3
Leg Dysppeak CPD stage
Total PADL
Combined
1.888
1.888
1.339
0.177
0.177
0.275
20.7
20.7
9.13
90.9
Leg Painpeak CPD stage
Total PADL
Combined
2.973
0.019
1.044
0.092
0.891
0.384
26.3
2.08
7.26
92.7
Arm Wattpeak CPD stage
Total PADL
Combined
3.015
0.005
1.424
0.090
0.943
0.250
26.1
1.08
9.65
90.7
Arm VO2peak CPD stage
Total PADL
Combined
1.524
2.882
1.485
0.224
0.097
0.233
18.5
25.5
10.0
90.0
Arm RPEpeak CPD stage
Total PADL
Combined
0.495
3.543
1.838
0.486
0.067
0.156
10.4
27.9
12.1
87.9
Arm Dysppeak CPD stage
Total PADL
Combined
0.022
0.299
0.110
0.896
0.632
0.954
0.62
7.61
0.82
99.2
Arm Painpeak CPD stage
Total PADL
Combined
2.195
1.000
1.126
0.146
0.323
0.350
22.5
15.2
7.79
92.2
Notes. Wattpeak = peak ergometry wattage, VO2peak = estimated peak VO2 (ml/kg/min), RPEpeak =
peak rating of perceived exertion, Dysppeak = peak dyspnoea, Painpeak = peak pain during
ergometry.
4.6. Physical Activity
4.6.1. GOLD group comparisons:
Table 4-17 reports the comparison of GOLD groups for physical activity measures. No significant
differences were found between the mild-moderate and severe-very severe groups for total,
vigorous, moderate and walking activity. The severe CPD group displayed lower (64%) scores for
vigorous activity compared to the mild-moderate CPD stage, although this was not statistically
significant (p=0.58) due to the high standard deviations.
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Table 4-18.
Comparison of GOLD groups for physical activity measures.
Total (n=44)
X ± SD
Mild-Moderate
(n=28)
X ± SD
Severe+
(n=16)
X ± SD
t-value p-value
Total activity* 3074 ± 3320 2838 ± 947 3209 ± 860 0.75 0.73
Vigorous activity* 313 ± 1042 380 ± 647 195 ± 1218 -0.56 0.89
Moderate activity* 2242 ± 2282 2178 ± 2194 2279 ± 2371 -0.14 0.57
Walking activity* 524 ± 762 558 ± 864 465 ± 559 -0.14 0.70
Note. *Activity measured in MET-minutes per week.
4.7. Partial Correlation
Partial correlations were consequently conducted to examine the relationships between
measures of pulmonary function, leg ergometry capacity (arm and leg), strength (leg and grip)
and physical activity levels (overall, lower body and upper body) while controlling for age, gender,
and BF% (Table 4-18). Total activity and the amount of upper and lower body activity showed no
statistically significant relationship (p>0.05) with measures of strength and aerobic capacity.
Predicted FEV1% displayed a weak non-significant (p>0.05) correlation with quadriceps strength
(r=0.30), and significant (p<0.05) moderate correlations with peak leg watt (r=0.42), peak arm
watt (r=0.33), and hamstring strength (r=0.41).
Peak arm ergometry watt presented a strong positive association with peak leg ergometry watt
(r=0.81, P<0.05). Peak leg watt demonstrated a moderate positive correlation with quadriceps
strength (r=0.51, p<0.05) and hamstring strength (r=0.47, p<0.05). Peak arm watt correlated
moderately with quadriceps strength (r=0.58, p<0.05) and hamstrings strength (r=0.51, p<0.05).
No correlation was found between peak arm watt and grip strength (r=-0.02).
Grip strength demonstrated a significant negative correlation with peak pain during leg ergometry
(r=-0.34, p<0.05). Arm pain and leg pain during ergometry had a moderate association (r=0.62,
p<0.05), while quadriceps and hamstrings strength demonstrated a high association (r=0.75,
p<0.05).
Perceived pain (arm and leg) during ergometry did not correlate with maximum wattage during
the 3rd stage of both the arm ergometry (arm pain r=0.04; leg pain r=-0.08) and leg ergometry
(arm pain r=0.23; leg pain r=-0.02) tests. In contrast, leg strength measures correlated moderately
with arm and leg ergometry wattage (arm watt r=0.58; leg watt r=0.51, p<0.05).
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Table 4-19.
Partial Correlations of the total group (n=44) between lung function, arm and leg ergometry
capacity, peripheral muscle strength, and PADL type and volume, controlling for age, gender,
and body fat percentage.
Leg
WattPeak
Leg
Painpeak
Arm
WattPeak
Arm
Painpeak
Grip
Strength
Quad
Strength
Ham
Strength
FVC% 0.29 -0.03 0.22 0.08 0.28 0.16 0.19
FEV1% 0.42* 0.12 0.33* 0.22 0.17 0.30 0.41*
Leg WattPeak - -0.02 0.81* 0.23 -0.13 0.51* 0.47*
Leg Painpeak -0.02 - -0.08 0.62* -0.34* 0.13 0.13
Arm WattPeak 0.81* -0.08 - 0.04 -0.02 0.58* 0.51*
Arm PainPeak 0.23 0.62* 0.04 - -0.28 0.16 0.10
Grip Strength -0.13 -0.34* -0.02 -0.28 - 0.28 0.13
Quad Strength 0.51* 0.13 0.58* 0.16 0.28 - 0.75*
Ham Strength 0.47* 0.13 0.51* 0.10 0.13 0.75* -
Quad Endur. 0.10 -0.29 0.05 -0.19 -0.13 -0.13 -0.17
Ham Endur. 0.01 -0.09 -0.03 -0.01 -0.08 0.11 0.02
Total activity 0.02 -0.09 0.15 -0.14 0.02 -0.11 -0.06
UB activity 0.14 -0.01 0.29 -0.02 -0.12 0.11 0.18
LB activity 0.30 0.01 0.16 0.24 -0.14 0.08 0.13
Note. VO2peak = estimated peak VO2 (ml/kg/min), Wattpeak = peak ergometry wattage, Painpeak =
peak pain during ergometry, Ham = hamstrings, Quad = quadriceps, Endur. = endurance, UB
= upper body, LB = lower body.
*Indicates statistical significance at p<0.05.
4.8. Prediction of Arm and Leg Ergometry Wattage
A regression analysis was conducted to determine whether quadriceps strength (Nm), grip
strength (kg) and FEV1% were predictive of peak wattage during submaximal leg ergometry
testing (Table 4-19). The adjusted R2 indicated that 64% of the variability in peak leg ergometry
wattage was explained by the independent variables. The F statistic was 26.387 with a
significance level of p=0.00, indicating that we can reject the null hypothesis.
Quadriceps strength showed the highest predictability of peak leg ergometry wattage (p=0.00,
beta 0.844 and t=6.238). The model predicts that for a one Nm increase in quadriceps strength
(peak torque), peak leg ergometry wattage would increase by 0.5W, holding grip strength and
FEV1% fixed. Furthermore, grip strength and FEV1% were significant predictors of peak leg
ergometry wattage (p=0.038, β=-0.270, t=-2.143 and p=0.028, β=-0.230, t=2.279, respectively).
The model predicts that a 1kg increase in grip strength would proliferate with a 0.5W increase in
peak leg ergometry wattage; and a 1% higher in FEV1 predicted value would increase peak leg
ergometry wattage by 0.2W.
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Table 4-20.
Regression analysis to determine whether quadriceps strength (Nm), grip strength (kg) and
FEV1% could predict peak wattage during submaximal leg ergometry testing.
Adjusted R2 F p-value
Model 1 0.693 26.387 0.000
B Std. Error Beta t p-value
Constant 3.678 7.110 0.517 0.608
Quad strength 0.461 0.074 0.844 6.238 0.000
Grip strength 0.496 0.232 0.270 2.143 0.038
FEV1% 0.241 0.106 0.230 2.279 0.028
A second regression analysis was conducted to determine whether quadriceps strength (Nm),
grip strength (kg) and FEV1% were predictive of peak wattage during submaximal arm ergometry
testing (Table 4-19). The adjusted R2 indicated that 53% of the variability in peak leg ergometry
wattage was explained by the independent variables. The F statistic was 17.018 with a
significance level of p=0.00, indicating that we can reject the null hypothesis.
Quadriceps strength was the only independent variable that showed predictability of peak arm
ergometry wattage (p=0.00, beta 0.793 and t=5.125). The model predicts that if you hold grip
strength and FEV1% fixed, a one Nm increase in quadriceps strength (peak torque), would equate
to a 0.3W higher peak arm ergometry wattage.
Table 4-21.
Regression analysis to determine whether peak wattage during submaximal arm ergometry
testing could be predicted by quadriceps strength (Nm), grip strength (kg) and FEV1%.
Adjusted R2 F p-value
Model 1 0.53 17.018 0.000
B Std. Error Beta t p-value
Constant 12.991 4.978 2.610 0.013
Quad strength 0.265 0.052 0.793 5.125 0.000
Grip strength 0.184 0.126 0.163 1.132 0.264
FEV1% 0.074 0.074 0.115 0.998 0.324
Quadriceps strength, as measured with an isokinetic dynamometer, was a statistically significant
contributor to leg wattage and arm wattage in the two regression analyses (Tables 4-19 and 4-
20). The results of the two standard regression analyses raised the question of how important leg
strength is, and whether it could be used as a predictor of arm ergometer capacity. Is arm wattage
dependent on the maintenance of leg strength?
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4.9. Prediction of Arm Ergometry Wattage from Quadriceps Strength
A binary logistic regression analysis was therefore conducted to predict peak arm ergometry
wattage with quadriceps strength (Table 4-21, Model 1). A test of the full model against the
constant only model was statistically significant, indicating that quadriceps strength distinguishes
with statistical significance between low and high arm ergometry wattage (chi square = 14.75,
p=0.001). The Nagelkerke R2 value indicated that quadriceps strength contributed 38.1% to the
variance of peak arm ergometry wattage (obtained during the 3rd stage of the graded arm
ergometry test).
The odds ratio was 13.76, indicating that if a CPD patient has high quadriceps strength they have
a 13.76 times higher odds of having high peak arm ergometry wattage. This odds ratio equates
to an 85.0% probability of having high arm ergometry peak wattage if quadriceps strength is high.
The probability of having low peak arm ergometry wattage in presence of high quadriceps strength
ability is 29.2%.
In Model 2, FEV1% and grip strength were added to the prediction model, which had a negative
impact on the prediction model, as the odd ratio decreased from 13.76 to 10.49. The chi square
value was non-significant (p=0.915), which indicated that adding FEV1% and grip strength does
not improve the model’s ability to predict arm ergometry wattage during the 3rd stage of the arm
ergometry test.
Table 4-22.
Binary logistic regression analysis to predict arm ergometry wattage with quadriceps strength
while controlling for stage of pulmonary disease, dyspnoea during physical activity and grip
strength.
Arm Ergometry Wattage
Quad
Strength
-2 Log
likelihood
Nagelkerke
R2
B S.E Wald OR (95% CI) p-
value
Model 1 45.883 0.381 2.62 0.77 11.58 13.76 3.04-62.32 0.00
Model 2 45.705 0.385 2.35 1.00 5.56 10.50 1.49-74.17 0.02
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Chapter 5. Discussion
5.1. Introduction
The primary aim of this thesis was to investigate the combined and individual contributions of
physical activities of daily living (type and volume) and FEV1 to arm and leg ergometry capacity
of patients with CPD. The secondary aim was to examine the predictability and odds ratio of high
arm and leg ergometry capacity in CPD individuals with high and low arm and leg strength, while
controlling for stage of disease, body composition and gender.
The main findings of the present thesis were that the volume of PADL performed with the upper
and lower body did not correlate with the respective upper and lower body strength or ergometry
capacity measures. Hence the first hypothesis that individuals engaging in more PADL involving
the arms and the legs will show better respective arm ergometry capacity and leg ergometry
capacity, can be rejected. The regression analyses revealed that stage of disease, handgrip
strength and leg strength contributed (p<0.05), independently from body composition and gender,
to leg ergometry capacity (peak wattage). Arm strength did not contribute statistically significantly
to arm ergometry capacity (peak wattage). Finally, the odds-ratio of the binary logistic regression,
to predict peak arm ergometry wattage with quadriceps strength, demonstrated that CPD patients
were 13.76 times more likely to have high peak arm ergometry wattage if their quadriceps strength
was high. The second hypothesis that arm and leg strength measures would predict arm and leg
ergometry capacity independently from body composition and gender, can consequently be
accepted. Leg strength measures had better predictability (with regard to both arm and leg
ergometry capacity) than handgrip strength.
5.2. Interpretation of main findings
5.2.1. Comparison of males and females
A comparison of sexes revealed that males and females were comparable in terms of age, weight,
FVC% and FEV1%. Females displayed a higher body fat percentage than males; and males
displayed higher grip, quadriceps and hamstring strength, arm and leg ergometry peak wattage
and VO2peak, and levels of vigorous activity and walking. These results were expected and have
been seen previously in CPD patients and healthy subjects (Carter et al., 2003; de Torres et al.,
2005). The differences found in anthropometric and physiological measurements between male
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and female participants revealed the importance of controlling for sex in the statistical analyses,
and acknowledging the differences when interpreting the findings of this thesis. However, due to
the small sample size there were not enough participants to further split the disease severity
groups in terms of sex.
5.2.2. Participant descriptive/anthropometric characteristics
In this thesis, disease severity was not statistically significantly associated with age or
anthropometric variables. A comparison of GOLD groups revealed that there were no significant
differences between mild-moderate and severe+ groups with regard to age, body mass, BMI or
BF% (Table 4-6). Furthermore, the factorial ANOVA revealed that there were no significant
differences for age, body mass, BMI or BF% between participants with low or high PADL levels
with mild-moderate or severe CPD (Table 4-7). These findings indicated that volume of physical
activity and severity of CPD as a combination show poor relationships with body composition, age
and gender. Similarly, it has been reported that FM and FFM were not important correlates of
physical activities of daily living (Monteiro et al., 2012), suggesting that body composition is
unrelated to the volume of PADLs performed in this population. In contrast to the findings of the
t-test and ANOVA, it has been reported that low BMI is more prevalent with increased disease
severity (Kim et al., 2014; Schols et al., 2005). However, Kim et al. (2014) concluded that the
prevalence in low FFM was higher than that of low BMI and emphasised the importance of
investigating specific aspects of body composition in addition to BMI.
Further investigation of the data (Table 4-7) revealed there was a noticeable (non-significant)
difference between the mild-moderate CPD (groups a and b) and the severe CPD (groups c and
d) groups with regard to age and the anthropometric variables. These differences might not
statistically significant due to large standard deviations and small samples sizes. Two participants
in particular had a causal influence on the standard deviations namely a woman that weighed
57kg (group b) and an elderly woman aged 71 years (group a). The individuals with severe + CPD
(groups c and d) are on average 6.6 years older than the individuals with Mild-moderate CPD
(groups a and b). Using the mean SD of groups a and b (because it’s the largest) this age
difference (between the mild-moderate and severe+ groups) equates to a moderate effect size
difference (6.6/12.9 = 0.51). The mean body mass differences of the mild-moderate (groups a
and b) and severe+ (groups c and d) also equate to a moderate effect size difference (11.7/21.7
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= 0.54).  This finding is captured by the ETA2 values presented in Table 4-8, which shows that
stage of disease contributed more to the variances of body mass, age, BMI and BF% than overall
participation in physical activity.
In summary, GOLD stage appeared to contribute more to the variances in age, body mass, BMI
and BF% than volume of physical activity, supporting the findings from previous studies that body
composition may be associated with disease severity (Harik-Khan, Fleg, & Wise, 2002; Kim et al.,
2014). Further investigation is needed to examine the complex interaction between body
composition, physical activity levels and disease severity in the CPD population.
5.2.3. Other measures of disease severity
A comparison of GOLD groups revealed that participants with mild-moderate airflow obstruction
presented with significantly higher FVC% predicted and a significantly lower MRC grade (Table
4-9). The significant differences between the GOLD groups for MRC grade and FVC%, and the
high correlation between FEV1% and FVC% (r=0.79) justified the use of airflow obstruction
(FEV1%) as a single measure when splitting the groups according to disease severity.
5.2.4. Upper and lower body strength and ergometry capacity
Disease severity (GOLD stage) was associated with measures of upper and lower body physical
functioning. The comparison of GOLD groups revealed that participants with mild-moderate
airflow obstruction displayed significantly stronger hamstrings and quadriceps, suggesting that
disease severity is associated with measures of lower body strength (Table 4-12). Additionally,
patients with mild-moderate airflow obstruction demonstrated a significantly higher leg ergometry
peak wattage and reduced leg fatigue scores than the severe group, indicating that those
individuals with severe CPD had greater lower body exercise limitations (Table 4-15). Disease
severity (FEV1% predicted) was moderately associated with peak arm and leg ergometry wattage,
suggesting that as CPD severity increases, both arm and leg functional capacity decreases.
Similar findings have been reported for patients with chronic airflow obstruction by Carter et al.,
(2003), who found moderate associations between FEV1 and peak arm ergometry wattage
(r=0.59, p<0.0001), and peak leg ergometry wattage (r=0.53, p<0.0001). Previous studies have
demonstrated moderate to high associations between FEV1 and max/peak leg ergometry wattage
(Haccoun et al., 2002), and VO2max (Gosselink et al., 1996).
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The findings of the present study and the above mentioned previously published literature verify
that disease severity (FEV1) is associated with measures of upper and lower body exercise
capacity and lower body strength. Due to the cross-sectional construction of this study no causal
conclusions can be made but the data does show moderate relationships between FEV1 (stage
of disease) and arm and leg ergometry capacity.
In the partial correlations (Table 4-19), peak leg ergometry wattage was associated with higher
quadriceps strength (r=0.51) and hamstring strength (r=0.47), which is in line with previous
studies who found associations between leg ergometry capacity and quadriceps strength
(Gosselink et al., 1996; Hamilton et al., 1995; Hillman et al., 2012). Interestingly, an association
was found between peak arm wattage and lower limb strength. None of the studies reviewed in
chapter 2 reported this association. This finding in the present thesis was unexpected and will be
discussed later in the chapter.
In the present study peak arm ergometry wattage was strongly associated with peak leg
ergometry (r=0.81, p<0.05). In terms of peripheral muscle strength, however, comparison of CPD
groups revealed that leg strength is more reduced in the severe CPD group than arm strength.
There was less of a difference between the two GOLD groups for grip strength (7%, p=0.47) than
quadriceps (19%, p=0.05) and hamstring strength (21%, p=0.04). A similar pattern was observed
by Franssen et al. (2002), who observed a preserved upper limb exercise capacity compared to
the lower limbs. The authors found that arm and leg peak wattage obtained during ergometry
testing were similar (50 ± 3 vs 61 ± 4W, respectively), but the upper limbs were deemed less
affected than the lower limb, as the maximum wattage of healthy controls for leg ergometry was
approximately double that of the arms (205 ± 13 vs 108 ± 7W). Overall the upper limbs had less
of a reduction than the controls, but similar functional values were found when the researchers
compared arms and legs in COPD patients (Franssen et al., 2002).
In contrast, Carter et al. (2003) found a reduction in arm ergometry ability of 38% in comparison
with leg ergometry, and indicated a greater metabolic demand for arm ergometry than leg
ergometry. Differences in findings between Carter et al. (2003) and this thesis may be attributed
to the study population, since only 38% of their study population were female, whereas, 64% of
the subjects in the present study were female. In addition, the mean FEV1% predicted values
were higher for both males and females in the present thesis compared to Carter et al. (2003)
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(55.21 ± 17.75% vs. 46.5 ± 10.9% for females, and 50.63 ± 19.71% vs. 40.2 ± 9.3% for males,
respectively).
Total PADL (minutes/week) and GOLD stage, as a combination, did not explain major parts of
the variability within any of the strength or ergometry capacity measures (Tables 4-14 and 4-17).
However, it is important to note that overall physical activity contributed more to the variances of
peak RPE during leg ergometry (10.4 versus 5.57), arm ergometry VO2peak (25.5 versus 18.5),
peak RPE during arm ergometry (27.9 versus 10.4) and peak arm ergometry dyspnoea (7.61
versus 0.62) than CPD stage (Table 4-17). Total PADL also evidenced larger contributions to the
variances of grip strength (21.5 versus 10.2), quadriceps endurance (20.3 versus 12.5) and
hamstring endurance (22.6 versus 9.74) in Table 4-14. This is in line with Andersson et al. (2013),
who found lung function, walking speed, and muscle strength to be important correlates of
physical activity in COPD patients. The strength of the relationships between overall participation
in physical activity and the mentioned measures of strength and aerobic capacity in the current
study is probably influenced by the fact that the participants in this study generally exhibited quite
low levels of participation in physical activity. Only 11 participants met the recommended
requirements for adequate/sufficient physical activity according to the IPAQ guidelines (IPAQ
research committee, 2005), while none of the participants met the ASCM recommendations. This
will be discussed in more detail in the Physical Activities of Daily Living section below.
5.2.5. Physical activities of daily living
In this thesis PADL was measured with the IPAQ, which was used in the t-tests, ANOVA and
partial correlations. The comparison of GOLD groups revealed that no statistically significant
differences between the mild-moderate and severe+ groups in terms of the total volume of PADL
performed (Table 4-18). The partial correlations analysis supported this finding, showing no
association (p>0.05) between disease severity (FEV1 and FVC) and the total volume and ratio of
upper and lower body PADL performed by CPD patients. However, while the total activity and the
moderate activity levels of the two GOLD groups (mild-moderate versus Severe+) were similar,
the mild-moderate group reported a 48.6% higher mean vigorous physical activity score than the
severe+ CPD group (Table 4-18). The non-significant, reduced levels of vigorous activity in the
severe+ group suggested that disease development impacted on the amount of high intensity
physical activity performed on a daily basis.
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In contrast to the findings of this thesis, previous studies have shown moderate associations
between physical inactivity and disease severity progression (Pitta, Troosters, Probst, Lucas et
al. (2006a); Watz et al., 2009b; Jehn et al., 2011; Katajisto et al., 2012; Andersson et al., 2013;
Hartman, Boezen, de Greef, & ten Hacken 2013), which may contribute to the loss of strength
and exercise capacity. Specifically, Andersson et al. (2013) reported that FEV1 explained
approximately 20% of the variability in physical activity levels in their study participants. Changes
in both total activity and lower limb activity have been related to FEV1, and higher levels of leg
activity have been reported among subjects with better FEV1 (Walker et al., 2008).
The Wilks Lambda scores reported for the ANOVA’s (Tables 4-14 and 4-17) suggested that total
PADL does not contribute (individually or in combination with CPD stage) much to the variances
of muscle strength and ergometry capacity. Additionally, the volume of total PADL performed with
the upper and lower body correlates poorly (p>0.05) with the respective measures of upper and
lower body strength or ergometry determined aerobic capacity (Table 4-19). Hence the first
hypothesis that individuals engaging in more PADL involving the arms and the legs will show
better respective arm ergometry capacity and leg ergometry capacity, can be rejected. The
hypothesis is rejected with acknowledgement that the data may be influenced by the low levels
of physical activity in the group.
Four participants (9%) displayed low activity levels (0-599 MET minutes/week); 29 participants
(66%) were moderately active (600-2999 MET minutes/week); and 11 participants (25%) were
highly active (>3000 MET minutes/week), according to the IPAQ classification guidelines (IPAQ
Research Committee, 2005). According to the ACSM guidelines for participation in physical
activity for older adults, all the participants in the current study can be classed as physically
inactive (Chodzko-Zajko et al., 2009). Differences between the IPAQ and the ACSM guidelines
are that ACSM refers to physical activity outside of PADLs and the IPAQ includes PADLs.
Regardless, of this difference only 25% of the participants, which were in the “highly active” group,
exhibited levels sufficient enough to achieve health benefits according to the IPAQ guidelines.
The type and volume of PADL performed may, therefore, not have been specific enough to
maintain upper and lower body strength and aerobic capacity.
The findings of Katajisto et al. (2012) may explain the small contribution of physical activity to
strength and aerobic capacity in the present study. The authors reported that sensation of
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dyspnoea, pain, and discomfort felt during strenuous exercise contributed to the physical inactivity
of patients with COPD. Discomfort or fear might have prevented the participants in the present
study from performing PADLs at intensity high enough to maintain or improve their peripheral
muscle strength and/or exercise capacity, which emphasises the importance of specified exercise
training in this population. To provide more insight into the low levels of physical activity in this
population investigation into the facilitators and barriers to physical activity in the CPD population
of New Zealand is needed. New Zealand weather, for example, may restrict individuals with CPD
to indoor activities, as varying weather conditions may exacerbate symptoms. No studies could
be found on New Zealand weather and its role as an exercise barrier in CPD patients, however,
detailed interviewing of the participants involved in the current study, prior to exercise testing (data
not reported), suggested that the weather in the Manawatu region of New Zealand might indeed
have been a factor that restricted involvement in outdoor PADL in this cohort.
The differences in the findings of this thesis and previously published literature, with regard to
participation in physical activity and its relationships with measures of aerobic capacity, may be
attributed to the self-report nature of the IPAQ. It is important to note that some participants may
have overestimated their actual physical activity levels, especially those who take longer to
perform activities due to a lower level of fitness, giving them an advantage as they look like they
are physically active for longer but in reality they are actually doing less activity overall. It is likely
that this is why the severe+ group displayed higher total PADL minutes than the mild-moderate
group (3209 ± 860 vs 2838 ± 947 min/week) in Table 4-18. It has been reported that for self-report
physical activity questionnaires participants are likely to underestimate sedentary activities and
overestimate aerobic activities (Klesges et al., 1990).
5.2.6. Prediction of arm and leg ergometry wattage
The standard regression analysis to predict peak leg ergometry wattage revealed that quadriceps
strength, FEV1% predicted and grip strength explained 64% of the variability in peak leg
ergometry wattage (Table 4-20). Quadriceps strength and FEV1 showed the highest predictability
of peak leg ergometry wattage (p=0.00, beta 0.844 and t=6.238, and p=0.028, β=-0.230, t=2.279,
respectively). These findings support previous studies in which leg strength has emerged as a
contributing factor to lower body exercise capacity and disease severity (Gosselink & Decramer,
1998; Steiner, Singh, & Morgan, 2005; Hillman et al., 2012). Peripheral muscle strength and
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FEV1% have an impact on lower limb aerobic capacity. Indeed, multivariate modelling has shown
that 76% of the variance in 6MWD could be explained by lung function, quadriceps strength and
lean leg mass (Hillman et al., 2012). Furthermore, in the present study grip strength was the third
significant predictor of peak leg ergometry wattage (Table 4-20, p=0.038, β=-0.270, t=-2.143),
indicating that upper body strength and lower body exercise capacity are interrelated. In support,
strong associations have been reported between handgrip strength and leg ergometry capacity
in COPD, namely VO2peak (r=0.73), VO2max (r=0.53) (Gosselink et al., 1996), and maximum
wattage (r=0.76) (Müller, Viegas, & Patusco, 2012). In addition, grip strength has been associated
with the 6MWT (r = 0.58) (Marino et al., 2010); and lat pull down 1RM (as a measure of upper
body strength) was found to be a predictive factor of 6MWD (R2=0.589) (Dourando et al., 2006).
Even though Marino et al. (2010) and Dourando et al. (2006) use different aerobic capacity and/or
strength measures compared to the present study, their findings still support that upper body
strength and lower body exercise capacity are related in CPD patients.
The second standard regression analysis to predict peak arm ergometry wattage revealed that
quadriceps strength, FEV1% predicted and grip strength explained 53% of the variability in peak
leg ergometry wattage (Table 4-21). Quadriceps strength was the only significant predictor of
peak arm ergometry wattage. In support, the partial correlation demonstrated a moderate
association between peak arm ergometry wattage and lower body strength (quadriceps r=0.58
and hamstring strength r=0.51, p<0.05). As mentioned previously in the chapter, no supporting
evidence could be found in the literature on the relationship between leg strength and arm
exercise capacity. However, previous studies have compared upper body strength with lower
body strength, and upper body aerobic capacity with lower body aerobic capacity in CPD.
Recently, Miranda, Malaguti, Marchetti, and Dal Corso (2014) compared middle deltoid and
quadriceps femoris strength and endurance of 21 CPD patients with a mean FEV1 of 46.1 ± 10.3%
predicted. The researchers found deltoid and quadriceps similar with regard to absolute strength,
but higher fatigability in the quadriceps indicating better upper body muscle (deltoid) fatigue
resistance. Likewise, Franssen et al. (2005) reported that quadriceps and biceps muscle function
are equally affected in severe COPD.
The binary logistical regression analysis revealed that respondents with high quadriceps strength
scores were 13.8 times more likely to have a higher wattage during sub-maximal arm ergometry
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testing. This equates to an 85.0% probability of having higher peak arm ergometry wattage if
participants have stronger quadriceps. In support, stepwise regression analysis revealed leg
strength to be the only significant contributor to performance during PADLs (Beta=0.547, t(22) =
2.92, p = 0.008) (Kato, Rodgers, Stickland, & Haennel, 2012). In the present study, quadriceps
strength contributed to arm and leg exercise capacity in patients with CPD. For the purpose of
the binary regression "high” and “low” peak wattage and quadriceps strength were split at the 60th
percentile (114Nm). Clinically, this indicated that individuals with quadriceps strength testing
scores below 114Nm have an 85% probability of not reaching 35W during the 3rd stage of arm
ergometry testing.
The present thesis contributed to current knowledge by conducting a binary regression analysis
to provide odds ratios and probabilities to predict arm and leg exercise capacity. The findings
complemented those of both Miranda et al. (2014) and Franssen et al. (2005) which indicated that
there is an association between upper and lower body function in terms of strength in CPD
patients. In addition to the association between upper and lower body strength in CPD, the
findings of the regression analyses demonstrated that quadriceps strength is not only associated
with upper body strength, but also predicts upper body aerobic capacity. Leg strength measures
had better predictability (with regard to both arm and leg ergometry capacity) than handgrip
strength.
Based on the above findings of the regression analyses the second hypothesis that leg and arm
strength measures would predict arm and leg ergometery capacity independently from body
composition and gender, can be accepted. The results of the standard and binary logistical
regression procedures conducted in this study indicated that upper body functional decline is
highly related to lower body decline. Quadriceps strength was predictive of both leg and arm
ergometry capacity. A potential explanation for this may be that commonly performed upper body
PADLs also include leg involvement. Therefore, if there is a reduction in lower limb function this
could cross over to upper body activities that require leg involvement.
5.3. Limitations
While the findings of this thesis provide novel insights into the contributions of upper and lower
body strength to upper and lower body exercise capacity, it is acknowledged that there are some
limitations to the present study that may impact on the reliability of the results and their
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interpretations. These primarily include limitations to physiological measurements, physical
activity measurement, and the sample size/study population.
5.3.1. Exercise capacity measurement
In the present study, only an indirect sub-maximal arm ergometry and leg ergometry method was
used to estimate VO2max.  Direct gas exchange measures were not used in this study due to
inaccessibility and safety of the participants, but it is acknowledged that cardiopulmonary exercise
testing would have improved the accuracy of peak oxygen uptake measurement. However,
medical supervision would have been required to perform maximal exercise testing for several
high risk CPD patients and this was not feasible for this study. In addition, wearing a mask during
exercise testing may pose additional anxiety and create more dyspnoea for the CPD patients. In
defence, the extrapolation method used to predict VO2peak from the YMCA submaximal leg
ergometer test has been shown to provide accurate predictions values (Beekley et al., 2004).
However, Garatachea, Cavalcanti, García-López, González-Gallego, and de Paz (2007) reported
that predicted VO2max was overestimated in healthy adults by 5.4% for men, and 11.8% for women
for the YMCA protocol. Taking this overestimation into consideration, and acknowledging the fact
that the participants in the present thesis were not healthy adults, peak intensity used in this study
was based on symptom limits (i.e. the actual intensity where exercise needed to be terminated
due to symptom limitation).
5.3.2. Physical activity measures
Daily physical activity was measured subjectively using the IPAQ. In a comparison of physical
activity questionnaires/diaries and motion sensors, Pitta, Troosters, Probst, Spruit et al. (2006b)
stated that care must be taken when using subjective methods of measuring PA, as they rely on
patient memory and report. Accelerometers and motion sensors are more reliable methods to
accurately quantify physical activity levels; however they can only accurately measure lower body
activity. Measurement of hand/arm movements involving the carrying or lifting of objects cannot
be tracked accurately. Questionnaires are inexpensive and easy to apply and provide subjective
insights of the patient’s views of their own physical activity levels; however, patients may
underestimate sedentary activities or overestimate their true level of physical activity by 300%
(Klesges et al., 1990). However, to enhance the reliability of our physical activity findings, the
IPAQ questionnaire was completed under supervision of the researchers, and careful interviewing
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of the participants was applied when recalling their physical activity of their last typical week in an
attempt to avoid any under or overestimation of weekly physical activity.
5.3.3. Sample size and study population
A convenience sample (n=44) of CPD patients was used for the study, which was limited by the
number of referrals to U-kinetics. It was not possible to control the number of participants, or the
number of participants in the various GOLD stages. Accordingly, participants with severe and
very severe CPD were grouped together, as were participants with mild and moderate CPD. The
limitation with this approach was that the impact of disease severity could not be tracked as
effectively as was intended. It may be useful to complete a study with a larger sample size and
enough participants in the separate GOLD stage groups to compare outcomes.
Diagnostic/classification guidelines for COPD are that airway obstruction is evident with a post-
bronchodilator FEV1/FVC of <0.7; and disease severity can be classed from mild to very severe,
which increases with a decrease in FEV1 (GOLD, 2014). This thesis included participants with a
COPD, chronic asthma, bronchiectasis, and obstructive sleep apnoea. Twelve subjects (27%)
had a reduced FEV1 but did not meet the < 0.7 ratio criteria, and were categorised as having
restrictive lung disease. However, since there were no differences seen between any outcome
measures when FVC and FEV1% predicted were compared, and the fact that all of the study
population showed some reduction in FEV1% predicted, the GOLD classification system based
on FEV1% predicted was used to determine severity of disease. Diffusion capacity of the lung for
carbon monoxide (DLCO) (the extent to which oxygen passes from the air sacs of the lungs into
the blood) could have been another option of an indicator of disease severity, however this was
not available for all participants.
5.4. Future Research
The present thesis aimed to determine whether FEV1, peripheral muscle strength, symptoms
during exercise and PADLs contributed to arm and leg ergometry capacity in participants with
CPD. While all of the participants had been diagnosed with a CPD they had several different
specific diagnoses. It would be useful to conduct a larger study with participants split into groups
according to their specific diagnosis, to determine whether each condition demonstrated the same
exercise limitations.
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Although this study provided new insights into the relationships between leg strength and arm
and leg ergometry, the impact of these variables on the participants quality of life was not
considered. To expand on the present study, it would be useful to investigate whether leg strength
and arm and leg ergometry capacity are associated with quality of life and/or self-efficacy
measures of patients with CPD. This would provide insight into how reductions in physical
functioning impact their everyday lives from the perception of the individual.
In the present study lower limb dysfunction (low quadriceps strength) was associated with a
reduced upper and lower body exercise capacity. Further investigation into the mechanisms
behind the reduction in lower limb strength in patients with CPD is needed. Lower limb muscle
dysfunction can be amendable through exercise rehabilitation strategies (Debigaré & Maltais,
2008), however investigation into the specific components of strength training in CPD needs more
attention. Would it be more beneficial to focus on lower limb strength training rather than
continuous aerobic exercise training? What are the most effective method and dosage of strength
training for improving primary outcomes?
Optimal exercise rehabilitation strategies need to be investigated to enhance the effectiveness of
exercise training in this population. It is apparent that physiological characteristics differ in patients
with CPD, and this is not necessarily related to stage of disease based on pulmonary function
alone. Given that, it is evident that research is required to address the magnitude of individual
responses from exercise training based on disease severity. Disease severity classification may
need to take into account the impact of the disease on strength, aerobic capacity, and ability to
perform PADLs. Exercise training programmes may need to be individualised to match the level
of physical disability each individual has as a result of their condition. This in turn might enhance
the understanding of how to gain maximum benefits from pulmonary rehabilitation to improve the
quality of life of patients with CPD.
Additionally, further investigation into the relationship between arm and leg exercise capacity,
peripheral muscle strength, and the ability to perform PADLs is needed. Investigation into how
the benefits of supervised exercise training may be translated into an increase in PADLs is
needed. The physical strain on patients with CPD during PADLs was not assessed in this study,
which may be a useful tool for determining the specific physical limitations in the everyday lives
of patients with CPD. Further investigation into the impact of CPD on overall functioning in the
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everyday lives of patients with CPD may identify specific limitations that could be amended with
exercise training, which may increase the volume and intensity of PADLs performed, and in turn
slow the progressing of the physical decline seen in these individuals.
Alternative testing methods to determine severity of CPD are needed, especially for patients who
are unable to perform spirometry due to contra-indications caused by co-morbidities. It would be
interesting to investigate whether measures of grip strength, quadriceps strength or aerobic
capacity may be used to identify disease severity in individuals where pulmonary function
measures are unavailable. Grip strength and leg strength may pose an alternative method of
assessing severity of disease if it is unsafe to perform spirometry, and to assess a patient’s need
for a funded pulmonary rehabilitation intervention. Leg strength can be easily assessed by hand-
held dynamometry or a 1RM test if an isokinetic device in unavailable. Grip strength is
inexpensive, quick to administer, requires minimal equipment, and can be easily performed. Grip
strength may also be able to identify those who will not perform well in leg ergometry testing and
may be helpful in estimating starting wattage and the level of the watt increments between the
stages.
5.5. Clinical Implications
The findings of this thesis demonstrate the importance of maintaining and/or improving upper and
lower body strength, in order to maintain arm and leg functional capacity. Upper and lower body
strength measures were more important contributors to the participant’s physical functioning than
their weekly volume of PADLs. This indicated that the intensity of physical activity was more
important than the amount of physical activity performed, as a higher intensity would place a
greater demand on the peripheral muscles and aerobic system.
The importance of leg strength in CPD is well known and current exercise training guidelines
include leg strength training as a part of rehabilitation of CPD patients. This thesis shows that
there is a high association of leg strength to both arm and leg aerobic capacity, emphasising the
need for improving and maintaining leg strength. Attention needs to be given to gaining maximum
improvements in leg strength during exercise training interventions.
In addition, the inclusion of leg strength testing before an exercise training intervention is justified
in this study, to identify those who have reduced leg strength. A goal of amending this will be a
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key objective of the individual’s specific exercise programme. It also justifies the need to test leg
strength after rehabilitation interventions to monitor the effectiveness of exercise programmes on
improving leg strength.
5.6. Conclusion
In attempt to enhance the exercise training of CPD patients it is important to identify specific
exercise limitations in this population, and how much impact each limitation has on the overall
functioning of these individuals. Effective exercise rehabilitation programmes are important to
maximise the physical improvements gained by individuals with CPD so that they can maintain
an improved quality of life for longer. As a result, this will reduce the healthcare burden, and the
morbidity and mortality rates of patients with CPD.
It was well-established that lower limb muscle function is an important predictor of exercise
capacity and mortality in CPD. This study adds to the current literature by proposing that lower
limb muscle strength is an important contributor to arm exercise capacity in addition to leg
exercise capacity, as measured by arm and leg ergometry.
Leg strength and leg ergometry capacity were directly related to arm ergometry capacity. These
findings suggest that a reduction in leg function is associated with a reduction in arm function. It
is important to note that the findings of this thesis demonstrated merely an association between
upper and lower limb function, and does not indicate causation. However, a possible explanation
could be that commonly performed PADLs involve legs as well as arms. Therefore if lower limb
function is reduced and individuals with CPD start to avoid activities involving the legs, as a
consequence arm activities that also involve standing or walking might also be avoided.
The findings of this thesis highlight the importance of assessing upper and lower limb strength in
patients with CPD. This thesis endorses the incorporation of specified lower limb strength training
in pulmonary rehabilitation, especially for those with reduced strength and physical activity levels.
Pulmonary rehabilitation programs should incorporate both aerobic exercise and lower limb
strength training.
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Appendix A - Borg Scales
Borg CR10 scale (1998)
0 Nothing at all “No P”
0.3
0.5 Extremely weak Just noticeable
1 Very weak
1.5
2 Weak
2.5
3 Moderate Light
4
5 Strong Heavy
6
7 Very strong
8
9
10 Extremely strong “Max P”
11
 Absolute maximum Highest possible
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Borg Dyspnea Scale
0 None
0.5 Very, very slight
1 Very slight
2 Slight
3 Moderate
4 Somewhat severe
5 Severe
6
7 Very severe
8
9 Very, very severe
10 Maximal
82
Borg’s Rating of Percieved Exertion Scale (RPE)
6
7 Very, very light
8
9 Very light
10
11 Fairly light
12
13 Somewhat hard
14
15 Hard
16
17 Very hard
18
19 Very, very hard
20
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Appendix B – MRC Grade
Medical Research Council dyspnoea scale (Tick one)
Grade Degree of breathlessness related to activities
1 Not troubled by breathlessness except on strenuous exercise
2 Short of breath when hurrying or walking up a slight hill
3 Walks slower than contemporaries on level ground because of
breathlessness, or has to stop for breath when walking at own
pace
4 Stops for breath after walking about 100m or after a few minutes
on level ground
5 Too breathless to leave the house, or breathless when dressing
or undressing
Adapted from Fletcher C.M., Elmes P.C., Fairbairn A.S. et al. (1959). The significance of
respiratory symptoms and the diagnosis of chronic bronchitis in a working population.
British Medical Journal, 2:257-66.
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Appendix C – ADL-D Scale
The Activity of Daily Living Dyspnoea scale
Name
 For each activity listed below, please rate your breathlessness on a
scale between 0 and 4, where 4 is not at all and 0 is maximally severe.
 If you find some activities are not performed by you, please give your
best estimate of breathlessness if you were to perform the task.
 Your responses should be for an ‘average’ day during the past week.
 Please response to all items.
Not at
all
Slight Severe Very
Severe
Maximally
Severe
Walking on level ground 4 3 2 1 0
Walking upstairs 4 3 2 1 0
Waking uphill 4 3 2 1 0
Walking inside the home 4 3 2 1 0
Straining to pass a bowel
motion 4 3 2 1 0
Putting on and taking off
jacket 4 3 2 1 0
Putting on and taking off
trousers 4 3 2 1 0
Putting on and taking off
socks 4 3 2 1 0
Washing face 4 3 2 1 0
Brushing teeth 4 3 2 1 0
Washing hair 4 3 2 1 0
Washing one’s back 4 3 2 1 0
Washing feet 4 3 2 1 0
Bending over 4 3 2 1 0
Shopping 4 3 2 1 0
© 2009 Asian Pacific Society of Respirology
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Appendix D – IPAQ
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Appendix E – Full Results Tables
Table 1.
Descriptive data of all participants and gender differences.
Total X ± SD
(n=44)
Male X ± SD
(n=16)
Female X ± SD
(n=28)
p-value
Age 59.80 ± 11.92 63.50 ± 9.18 57.68 ± 12.91 0.12
Weight 87.28 ± 20.58 89.45 ± 13.89 86.04 ± 23.72 0.60
BMI 33.15 ± 10.98 29.69 ± 4.06 35.13 ± 13.10 0.11
BF% 30.56 ± 13.08 20.41 ± 7.71 36.36 ± 11.98 <0.001
FVC% 70.64 ± 13.22 71.13 ± 13.03 70.36 ± 13.55 0.86
FEV1% 54.64 ± 18.27 50.63 ± 19.71 55.21 ± 17.75 0.78
Leg VO2peak 21.84 ± 5.86 24.34 ± 6.73 20.42 ± 4.88 0.03
Leg Wattpeak 49.32 ± 19.13 57.81 ± 20.16 44.46 ± 17.02 0.02
Leg Painpeak 3.31 ± 1.82 2.81 ± 1.61 3.61 ± 1.89 0.17
Arm VO2peak 21.59 ± 6.29 21.67 ± 6.64 21.54 ± 6.20 0.95
Arm Wattpeak 38.86 ± 11.71 45.00 ± 12.78 35.36 ± 9.62 0.01
Arm Painpeak 3.29 ± 1.52 3.34 ± 1.62 3.26 ± 1.49 0.86
Grip strength 30.92 ± 10.39 41.13 ± 8.64 25.09 ± 5.79 <0.001
Quad strength 103.67 ± 34.99 129.38 ± 24.62 88.98 ± 31.59 <0.001
Ham strength 53.10 ± 19.47 66.94 ± 15.96 45.20 ± 16.85 <0.001
Quad endur 88.42 ± 14.11 88.88 ± 12.31 88.16 ± 15.26 0.87
Ham endur 98.71 ±30.94 90.09 ± 16.83 103.63 ± 36.03 0.17
Total activity 3074 ± 3320 3342 ± 4586 2921 ± 2408 0.69
Vigorous activity 313 ± 1042 798.13 ± 1643 36 ± 103 0.02
Moderate activity 2242 ± 2282 1743 ± 2269 2528 ± 2281 0.28
Walking activity 524 ± 762 815 ± 1149 358 ± 333 0.05
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Table 2.
Comparison of Mild-Moderate and Severe+ CPD groups.
Mild-Moderate
(n=28)
Mean SD
Severe+
(n=16)
Mean SD
t-value p-value
Age 57.25 ± 13.52 64.25 ± 6.70 1.93 0.06
BMI 35.15 ± 12.83 29.65 ± 5.37 -1.63 0.11
BF% 32.31 ± 14.00 27.49 ± 11.04 -1.18 0.24
FVC% 75.18 ± 11.44 62.69 ± 12.62 -3.36 0.002
FEV1% 65.93 ± 10.69 34.88 ± 9.81 -9.54 0.0001
MRC Grade 1.96 ± 0.74 2.75 ± 0.86 3.19 0.003
Peak VO2 leg 22.83 ± 6.38 20.12 ± 4.50 -1.50 0.14
Peak VO2 arm 22.42 ± 6.48 20.13 ± 5.85 -1.16 0.25
Peak W leg 54.11 ± 20.95 40.93 ± 11.86 -2.30 0.03
Peak W arm 41.25 ± 11.81 34.69 ± 8.26 -1.84 0.07
Peak pain leg 3.28 ± 1.74 2.69 ± 1.83 -1.78 0.08
Peak pain arm 3.55 ± 1.57 2.83 ± 1.36 -1.54 0.13
Grip strength 31.79 ± 10.55 29.41 ± 10.27 -0.73 0.47
Quad strength 111.29 ± 37.70 90.34 ± 25.58 -1.97 0.055
Ham Strength 57.52 ±21.02 45.38 ± 13.83 -2.06 0.045
Quad endurance 87.23 ± 14.05 90.50 ± 14.43 0.73 0.47
Ham endurance 96.34 ± 25.17 102.84 ± 39.68 0.67 0.50
Total activity 2837.91 ± 947.35 3208.96 ± 860.31 0.75 0.73
Moderate activity 2177.5 ± 2193.7 2279.3 ± 2370.5 -0.14 0.89
Vigorous activity 380.27 ± 647.17 195.31 ± 1218.31 -0.56 0.57
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Table 3.
Combined and individual relationships of CPD stage and Physical Activity with morphological,
cardiovascular and strength variables as determined with a factorial ANOVA.
CPD Stage
Total PADL
(min/week)
Mild-Moderate Severe +
X SD X SD
Age Low a 55.69 16.22 c 4.50 5.58
High b 59.33 9.61 d 64.00 8.05
Body Mass Low a 95.74 14.57 c 77.41 16.27
High b 86.46 29.02 d 81.45 15.58
BMI Low a 37.65 14.39 c 27.98 4.84
High b 31.81 10.00 d 31.33 5.61
Percentage body fat Low a 35.20 14.35 c 24.36 8.50
High b 28.46 13.11 d 30.61 12.90
MRC Grade Low a 1.88c 0.61 c 3.1 a b 0.83
High b 2.08c 0.90 d 2.38 0.74
ADL/Dyspnea Low a 51.97 7.23 c 49.86 4.91
High b 49.92 7.44 d 50.38 4.67
FVC% Low a 77.38c d 13.56 c 62.12a 12.29
High b 72.25 13.22 d 63.13a 13.77
Peak watt (leg) Low a 58.75 20.04 c 41.88 14.62
High b 47.92 21.36 d 40.00 9.26
Peak VO2 (leg) Low a 22.44 4.73 c 19.40 5.15
High b 23.35 8.30 d 20.83 3.95
Peak RPE bike Low a 12.81 1.64 c 12.86 1.73
High b 12.71 2.22 d 12.25 0.89
Peak Dyspnea (bike) Low a 2.86 1.20 c 3.69 1.33
High b 2.71 0.84 d 2.86 1.16
Peak Pain (bike) Low a 3.72 1.26 c 2.56 2.16
High b 3.63 2.30 d 2.81 1.56
Peak watt (arm) Low a 42.81 10.16 c 33.13 9.61
High b 39.17 15.93 d 36.25 6.94
Peak VO2 (arm) Low a 21.72 5.63 c 17.65 5.85
High b 23.35 7.63 d 22.62 5.00
Peak RPE (arm) Low a 12.69 1.66 c 13.13 0.99
High b 12.58 1.56 d 11.50 1.20
Peak Dyspnea (arm) Low a 2.41 0.71 c 2.50 1.54
High b 2.38 1.15 d 2.19 1.33
Peak pain (arm) Low a 3.66 1.60 c 3.19 1.51
High b 3.42 1.58 d 2.48 1.19
Grip strength Low a 32.97 9.66 c 32.63 13.12
High b 30.21 11.87 d 26.19 5.50
Quad strength Low a 116.8
8
38.02 c 98.06 33.79
High b 103.8
3
37.55 d 82.63 11.16
Hamstring strength Low a 61.50 21.19 c 44.50 18.08
High b 52.21 20.44 d 46.25 9.02
Quad endurance Low a 89.41 10.68 c 93.88 17.87
High b 84.33 17.70 d 87.13 10.03
Hamstring endurance Low a 94.59 12.72 c 119.31 48.72
High b 98.67 36.36 d 86.38 19.51
Note. Group a = mild-moderate CPD and low PADL level (n= 16), group b = mild-moderate CPD and high
PADL level (n= 12), group c = severe+ CPD and low PADL level (n= 8), and group d = severe+ CPD and
high PADL level (n= 8).
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Table 4.
The f-ratio, p-values, ETA2 and Wilks Lambda scores of the factorial ANOVA investigating the relationship
of CPD stage and total PADL (min) with arm and leg ability (strength and peak watt during ergometry) in
CPD patients.
Dependent variables ANOVA groups F-ratio p-values Eta2 Wilks
Lambda
Age CPD stage
Total PADL
Combined
3.326
0.181
1.428
0.076
0.673
0.249
27.4
6.39
9.67
90.3
Body Mass CPD stage
Total PADL
Combined
3.438
0.173
1.836
0.071
0.679
0.156
27.5
6.17
12.1
87.9
BMI CPD stage
Total PADL
Combined
2.267
0.137
1.701
0.140
0.713
0.182
22.4
5.51
11.3
88.7
Percentage body fat CPD stage
Total PADL
Combined
1.143
0.004
1.411
0.292
0.951
0.254
16.1
0.94
9.57
90.4
FVC% CPD stage
Total PADL
Combined
10.356
0.282
4.121
0.003
0.598
0.012
44.5
7.33
23.6
76.4
MRC Grade CPD stage
Total PADL
Combined
10.257
1.266
5.030
0.003
0.267
0.005
43.1
15.2
27.4
72.6
ADL/Dyspnea CPD stage
Total PADL
Combined
0.159
0.143
0.306
0.693
0.708
0.821
6.23
5.90
2.24
97.6
Peak watt (leg) CPD stage
Total PADL
Combined
4.725
1.242
2.622
0.035
0.272
0.064
31.4
16.1
16.4
83.6
Peak VO2 (leg) CPD stage
Total PADL
Combined
2.247
0.395
0.852
0.142
0.533
0.474
22.9
9.63
6.01
94.0
Peak RPE bike CPD stage
Total PADL
Combined
0.131
0.444
0.228
0.719
0.509
0.877
5.57
10.4
1.68
98.3
Peak Dyspnea (bike) CPD stage
Total PADL
Combined
1.888
1.888
1.339
0.177
0.177
0.275
20.7
20.7
9.13
90.9
Peak Pain (bike) CPD stage
Total PADL
Combined
2.973
0.019
1.044
0.092
0.891
0.384
26.3
2.08
7.26
92.7
Peak watt (arm) CPD stage
Total PADL
Combined
3.015
0.005
1.424
0.090
0.943
0.250
26.1
1.08
9.65
90.7
Peak VO2 (arm) CPD stage
Total PADL
Combined
1.524
2.882
1.485
0.224
0.097
0.233
18.5
25.5
10.0
90.0
Peak RPE (arm) CPD stage
Total PADL
Combined
0.495
3.543
1.838
0.486
0.067
0.156
10.4
27.9
12.1
87.9
Peak Dyspnea (arm) CPD stage
Total PADL
Combined
0.022
0.299
0.110
0.896
0.632
0.954
0.62
7.61
0.82
99.2
Peak pain (arm) CPD stage
Total PADL
Combined
2.195
1.000
1.126
0.146
0.323
0.350
22.5
15.2
7.79
92.2
Grip strength CPD stage 0.441 0.511 10.2 94.1
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Overall Act
Combined
1.957
0.841
0.170
0.479
21.5
5.94
Quad strength CPD stage
Overall Act
Combined
3.514
1.779
1.906
0.068
0.190
0.144
27.7
19.7
12.5
87.5
Hamstring strength CPD stage
Overall Act
Combined
3.753
0.405
1.978
0.059
0.528
0.133
28.6
9.39
12.9
87.1
Quad endurance CPD stage
Overall Act
Combined
0.658
1.745
0.770
0.422
0.194
0.518
12.5
20.3
5.46
94.5
Hamstring endurance CPD stage
Overall Act
Combined
0.430
2.321
1.795
0.516
0.135
0.164
9.74
22.6
11.9
88.1
